
Title: Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Rising Dose Study to 
Evaluate Pharmacokinetics, Safety, and Tolerability of TAK-788 Followed by Open-Label, 
Crossover Evaluation of the Effects of a Low-Fat Meal on TAK-788 Pharmacokinetics and 
Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Subjects
Study ID: [REMOVED]
Protocol Approve Date: 13 November 2018 
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
1.0 TITLE PAGE
PROTOCOL
Phase 1, Randomized, Double -blind, Placebo- Controlled, Single Rising Dose Study to 
Evaluate Pharmacokinetics, Safety, and Tolerability of TAK- 788 Followed by Open -Label, 
Crossover Evaluation of the Effects of a Low -Fat Meal on TAK -788 Pharmacokinetics and 
Evaluation of Relative Bioavailability of TAK -788 Capsules in Healthy Subjects
Sponsor: Millennium Pharmaceut icals, Inc., a wholly owned subsidiary of Takeda 
Pharmaceut ical Co mpany Limited
40 Landsdowne Street
Cambridge, MA 02139 USA
Telephone: +1 (617) 679 -7000
Please note: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda 
Pharmaceutical Company Limited, may be referred to in this protocol as 
“Millennium”, “sponsor”, or “Takeda” .
Study Number: TAK -788-1001
IND Num ber: 126,721 EudraCT Number: Not applicable
Compound: TAK -788 (form erly AP32788)
Date: 13 November 2018 Amendment Number: 03
Amendment History :
Date Amendment Number Amendment Type Region
08 February 2018 Initial Protocol Not applicable Global
13 June 2018 01 Substantial Global
02 November 2018 02 Substantial Not applicable a
13 November 2018 03 Substantial Global
aProtocol Amendment 02 was not activated.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 2of 92
Protocol Incorporating Amendment 03 13 November 2018
1.0 ADMINISTRATIVE 
1.1 Contacts 
A separate contact informat ion list will be provided to each site.
Serious adverse event (SAE) and pregnancy reporting informat ion is presented in Section 10.0, as 
is informat ion on reporting product complaints.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevant guidelines 
provi ded to the si te.
Contact Type/Role United States Contact
Serious adverse event and pregnancy reporting See Section 10.0.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 3 of 92
Protocol Incorporating Amendment 03 13 November 2018
1.2 Approval 
REPRESENTATIVES OF TAKEDA This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protoc ol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation (ICH) E6 Good Clinical Practice (GCP): 
Consolidated Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can 
be found on the signature page.
Electronic si gnatures may be found on the last page of this document.
PPD
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Usedance dance 
wing:wing:
e (GCP):(GCP
ta privacpriva
other sigther si
this dochis do
For non-commercial use only an
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 4of 92
Protocol Incorporating Amendment 03 13 November 2018
INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the investigator’s brochure, and any 
other product information provided by the sponsor. I ag ree to conduct this study  in accordance 
with the requirements of this protocol and also to protect the rights, safet y, privacy, and well -being 
of study  subjects in accordance with the following:
The ethical principles that have their origin in the Declarat ion of Helsinki.
ICH, E6 GCP: Consolidated Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion 10.0 of this 
protocol .
Terms outlined in the clinical study  site agreement.
Responsibilit ies o f the Invest igator (Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y(Country )
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 5of 92
Protocol Incorporating Amendment 03 13 November 2018
1.3 Protocol Amendment 03 Summary of Changes
Rationale for Amendment 03
This document describes the changes in reference to the protocol incorporating Amendment 03. 
As Protocol  Amendment 02 was not activated, the changes described below are based on a 
comparison with Amendment 01. The primary reason for this amendment is to add Part 3 to assess 
the relative bioavailabilit y of the single dose of TAK -788 160 m g administered as Process B 
drug-in-capsule (Di C) (test) versus a single dose of TAK -788 16 0 mg administered as Process A 
DiC (reference) in healt hy subjects.
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion and administrative purposes only.
For specific de scriptions of text changes and where the changes are located, see Appendix E.
Changes in Amendment 03 (Compared with Amendment 01)
1.Addit ion of Part 3 to assess the relat ive bioavailabilit y of TAK -788 capsules in healt hy 
subjects.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 6of 92
Protocol Incorporating Amendment 03 13 November 2018
TABLE OF CONTENTS
1.0 ADMINISTRATIVE ....................................................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 03 Summary  of Changes .......................................................... 5
2.0 STUDY SUMMARY .................................................................................................... 11
3.0 STUDY REFERENCE INFORMATION ...................................................................... 19
3.1 Study -Related Responsibilit ies................................................................................. 19
3.2 Principal Invest igator/Coordinating Invest igator ...................................................... 19
3.3 List of Abbreviat ions............................................................................................... 20
3.4 Corporate Identificat ion........................................................................................... 21
4.0 INTRODUCTION ......................................................................................................... 22
4.1 Scientific Background .............................................................................................. 22
4.2 Nonclinical Experience ............................................................................................ 23
4.3 Clinical Experience .................................................................................................. 23
4.4 Rationale for the Proposed Study ............................................................................. 24
4.4.1 Risk-Benefi t Assessment .................................................................................... 24
4.4.2 Rationale for Single Dose Escalat ion(Part 1) ..................................................... 24
4.4.3 Rationale for Food Interaction (Part 2) ............................................................... 25
4.4.4 Rationale for Rel ative Bioavailabilit y Assessment (Part 3) .................................26
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 27
5.1 Object ives................................................................................................................ 27
5.1.1 Primary Object ives............................................................................................. 27
5.1.2 Secondary  Object ives......................................................................................... 27
5.1.3 Exploratory  Objectives ....................................................................................... 27
5.2 Endpoints ................................................................................................................. 27
5.2.1 Primary Endpo ints............................................................................................. 27
5.2.2 Secondary  Endpo ints.......................................................................................... 28
5.2.3 Exploratory  Endpo ints....................................................................................... 28
6.0 STUDY DESIGN .......................................................................................................... 30
6.1 Overview of Study  Design ....................................................................................... 30
6.1.1 Part 1 –Dose Escalation ..................................................................................... 30
6.1.2 Part 2 –Food Effect ........................................................................................... 31
6.1.3 Part 3 –Relative Bioavailabilit y......................................................................... 32
6.2 Number of Subjects .................................................................................................33
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 7of 92
Protocol Incorporating Amendment 03 13 November 2018
6.3 Durati on of  Study .................................................................................................... 34
6.3.1 Durati on of  an Individual Subject’s Study  Parti cipati on..................................... 34
6.3.2 End of Study /Study  Com pletion Definit ion and Pl anned Reporting .................... 34
6.3.3 Time Frames for Primary  and Secondary  Endpoints to Support Disclosures ....... 34
6.3.4 Total  Study  Durati on.......................................................................................... 36
7.0 STUDY POPULATION ................................................................................................ 37
7.1 Inclusio n Cri teria..................................................................................................... 37
7.2 Exclusio n Cri teria.................................................................................................... 37
8.0 STUDY DRUG ............................................................................................................. 40
8.1 Study  Drug Administration ...................................................................................... 40
8.1.1 Dose Escal ation Phase (Part 1) ........................................................................... 40
8.1.2 Food Effects Study  Phase (Part 2) ...................................................................... 40
8.1.3 Relative Bioavailabilit y (Part 3) ......................................................................... 41
8.2 Definit ions of DLT .................................................................................................. 42
8.3 Dose Escal ation Rules .............................................................................................. 42
8.4 Criteria for Tol erable Dose ...................................................................................... 42
8.5 Excluded Conco mitant Medi cations and Procedures ................................................ 42
8.6 Permi tted Concomitant Medications and Procedures ................................................ 43
8.7 Precauti ons and Restri ctions.................................................................................... 43
8.8 Management of Selected EGFR TKI Class AEs ....................................................... 44
8.8.1 Pneumo nitis....................................................................................................... 44
8.8.2 Nausea and Vomit ing......................................................................................... 45
8.8.3 Diarrhea ............................................................................................................. 45
8.9 Blinding a nd Unblinding .......................................................................................... 45
8.10 Descript ion of Invest igational Agents ...................................................................... 45
8.11 Preparati on, Reconstitution, and Dispensat ion.......................................................... 46
8.12 Packaging and Labeling ................................
........................................................... 46
8.13 Storage, Handling, and Accountabilit y..................................................................... 46
8.13.1 Disposi tion of Used Supplies ............................................................................. 47
8.13.2 Inventory  of Unused Supplies ............................................................................ 47
8.14 Other Protocol -Specified Materials .......................................................................... 47
9.0 STUDY CONDUCT ...................................................................................................... 48
9.1 Study  Personnel and Organizations .......................................................................... 48
9.2 Arrangements for Recruit ment of Subjects ............................................................... 48
9.3 Treatment Group Assignments ................................................................................. 48
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 8of 92
Protocol Incorporating Amendment 03 13 November 2018
9.4 Study  Procedures ..................................................................................................... 48
9.4.1 Inform ed Consent ............................................................................................... 49
9.4.2 Subject Dem ographics ....................................................................................... 49
9.4.3 Medical History .................................................................................................49
9.4.4 Physical Examinat ion......................................................................................... 49
9.4.5 Subject Hei ght................................................................................................... 49
9.4.6 Vital Signs ......................................................................................................... 49
9.4.7 Pulm onary Function Tests .................................................................................. 49
9.4.8 Drug, Al coho l, and Tobacco Testing .................................................................. 49
9.4.9 Pregnancy Test ................................................................................................... 50
9.4.10 Concomitant Medications and Procedures .......................................................... 50
9.4.11 AEs.................................................................................................................... 50
9.4.12 Enrollment ......................................................................................................... 50
9.4.13 ECG ................................................................................................................... 50
9.4.14 Chest CT Scan ................................................................................................... 51
9.4.15 Clinical Laboratory  Evaluat ions......................................................................... 51
9.4.16 PK Measurements .............................................................................................. 52
9.5 Com pletion of Study  Treatm ent for Individual Subjects ........................................... 53
9.6 Discontinuati on of  Treatment Wi th Study  Drug and Subj ect Replacement ............... 53
9.7 Study  Com pliance .................................................................................................... 54
10.0 ADVERSE EVENTS .................................................................................................... 55
10.1 Definit ions............................................................................................................... 55
10.1.1 PTE.................................................................................................................... 55
10.1.2 AE Definit ion.................................................................................................... 55
10.1.3 SAE Definit ion.................................................................................................. 55
10.2 Procedures for Recording and Reporting AEs and SAEs .......................................... 56
10.3 Moni toring of AEs and Period of Observat ion......................................................... 57
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events ......... 57
10.5 Procedures for Reporting Product Complaints or Medicat ion Errors (Including 
Overdose) ................................................................................................................ 57
10.6 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties........... 58
11.0 STUDY COMMITTEES ............................................................................................... 59
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 60
12.1 eCRFs ...................................................................................................................... 60
12.2 Record Retention ..................................................................................................... 60
13.0 STATISTICAL METHODS .......................................................................................... 62
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 9of 92
Protocol Incorporating Amendment 03 13 November 2018
13.1 Statistical and Analyt ical Plans ................................................................................ 62
13.1.1 Analysis Sets ...................................................................................................... 62
13.1.2 Analysis of Demographics and Other Baseline Characterist ics........................... 62
13.1.3 PK Analysis ....................................................................................................... 62
13.1.4 Safety Analysis .................................................................................................. 63
13.2 Determinat ion of Sample Size .................................................................................. 64
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 65
14.1 Study -Site Moni toring Visit s................................................................................... 65
14.2 Protocol  Deviat ions.................................................................................................. 65
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 65
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 66
15.1 IRB and/or IEC Approval ........................................................................................ 66
15.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 67
15.3 Subject Confidentialit y............................................................................................ 68
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................68
15.4.1 Publicat ion......................................................................................................... 68
15.4.2 Clinical Tri al Registrati on.................................................................................. 69
15.4.3 Clinical Trial Result s Disclosure ........................................................................ 69
15.4.4 Data Sharing ...................................................................................................... 69
15.5 Insurance and Co mpensation for Injury .................................................................... 69
16.0 REFERENCES .............................................................................................................. 70
LIST OF IN -TEXT TABLES
Table 6.a Primary and Secondary  Endpo ints for Di sclosures ............................................. 35
Table 8.a Low-fat Meal  Content ........................................................................................ 41
Table 8.b Contraceptive Methods ...................................................................................... 44
Table 9.a Clinical Chemistry  and Hematol ogy Tests .......................................................... 51
Table 9.b Clinical Urinalysis Tests .................................................................................... 52
LIST OF IN -TEXT FIGURES
Figure 6.a Dose Escal ation Schema (Part 1) ........................................................................ 31
Figure 6.b Food Effect Schem a (Part 2) .............................................................................. 32
Figure 6.c Relative Bioavailabilit y Schema (Part 3) ............................................................ 33
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 10of 92
Protocol Incorporating Amendment 03 13 November 2018
LIST OF APPENDICES
Appendix ASchedule of Events ............................................................................................. 72
Appendix BResponsibilit ies o f the Invest igator ..................................................................... 81
Appendix CInvest igator Consent to Use of Personal Informat ion.......................................... 83
Appendix DList of Strong Inhibitors and Ind ucers of CYP3A ............................................... 84
Appendix EDetailed Descript ion of Amendments to Text ..................................................... 85
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 11of 92
Protocol Incorporating Amendment 03 13 November 2018
2.0 STUDY SUMMARY
Name of Sponsor:
Millennium Pharmaceuticals, Inc Compound:
TAK -788 (formerly AP32788)
Title of Protocol: Phase 1, Randomized, Double -blind, 
Placebo -Controlled, Single Risi ng Dose Study to Evaluate 
Pharmacokinetics, Safety, and Tolerability of TAK -788 
Followed by Open -Label, Crossover Evaluation of the 
Effects of a Low -Fat Meal on TAK -788 Pharmacokinetics 
and Evaluation of Relative Bioavailability of TAK -788 
Capsules in Heal thy Subjects IND No.: 
126,721EudraCT No.: 
Not applicable 
Study Number: TAK -788-1001 Phase: 1
Study Design:
This is a randomized, double -blind, placebo -controlled single rising dose study, followed by an open -label, crossover 
evaluation of the effects of a low -fat meal on the pharmacokinetics (PK) of TAK -788 and its 2 active metabolites in 
healthy  subjects, and a crossover evaluation of the relative bioavailability of TAK -788 Process B DiC (test) versus 
Process A DiC (reference) in healthy subjects under fasting conditions. Following the completion of Part 1 (dose 
escalation phase) where a safe and tolerable dose in healthy  subjects will be identified, Part 2 (food effect phase) and 
Part 3 (relative bioavailability of TAK -788 capsules) will be initiated where the effects of a low -fat meal on TAK -788 
and the relative bioavailability of TAK -788 in test versus refere nce will be studied. 
Part 1 –Dose Escalation:
In the double -blind, randomized, placebo -controlled dose escalation phase, cohorts of 8 healthy subjects will be 
randomized: Under fasting conditions, 6 subjects will receive a single dose of TAK -788 and 2 su bjects will receive 
placebo. The starting dose will be 20 mg then with each subsequent 8-subject cohort the dose will escalate to a single 
dose of 40, 80, 120, up to 160 mg. Dose escalation can occur if there are no dose -limiting toxicities following 
admin istration of TAK -788 and all Grade ≥2 treatment -related adverse events (AEs) resolve to Grade ≤1 or return to 
baseline by Day 5. If all treatment -related Grade ≥2 AEs have not resolved to Grade 1 or returned to baseline by Day 5, 
the assessment will be rep eated on Day 8 and Day 15, if necessary, before proceeding to the next planned higher dose. 
The subjects will remain at the clinical study site for at least 48 hours postdose for close safety monitoring. The 
subjects will be furloughed from the site 48 hours postdose if there are no Grade ≥2 AEs. Subjects will return to the 
site for the PK sample collection on Days 4, 5, and 8. A final safety phone conference will occur 30 days after the last 
dose (window of up to 2 days after Day 30).
Additional cohorts may also be enrolled in Part 1 to assess the safety, tolerability, and PK of single -dose TAK -788 
DiC containing TAK -788 active pharmaceutical ingredient from a different synthetic process (such as Process A). The 
dose(s) in the additional cohort(s) will b e determined by the safety, tolerability, and PK exposure data from the 
completed cohorts in this study and the experience in the ongoing phase 1/2 study in patients with non –small - cell lung 
cancer (Study AP32788 -15-101). The highest dose tested in Part 1 of the study will not exceed the unit dose of the 
maximum tolerated dose identified in Study AP32788 -15-101. 
To mitigate the risk of treatment, pulmonary function tests (PFTs) (spirometry, lung volumes, and diffusion capacity 
[DLco]) and a chest computed tomography (CT) scan are required to be performed and assessed to be normal (PFTs 
≥80% of predicted normal) at screening; baseline PFTs to be performed no more than 7 days before Day 1. At 
48hours postdose before furlough, PFTs will be performed and pulmo nary symptoms assessed. If the DLco has 
decreased by >20% of baseline or the subject reports pulmonary symptoms on Day 3, a chest CT scan will be 
performed. Any DLco abnormalities or chest CT scan abnormalities will be followed weekly until resolution. An 
appropriate treatment will be initiated by the investigator or attending pulmonologist in the event of clinically 
significant pulmonary symptoms, abnormal DLco, and/or abnormal chest CT scan.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 12of 92
Protocol Incorporating Amendment 03 13 November 2018
Study Schema for Single Rising Dose Phase (Part 1)
DiC, drug -in-capsule. 
Part 2 –Food Effect:
In the food effect part of the study, all subjects will receive TAK -788 only. Subjects will be randomized to a crossover  
sequence at a 1:1 ratio and administered the dose of TAK -788 identified in Part 1 on Day 1 in Period 1 and on Day 8 
in Period 2 with a low -fat meal (Treatment A) or under fasting conditions (Treatment B) with a washout period of ≥7 
days between each dose of TAK -788. The duration of the washout period may be updated pending the PK results from 
Part 1. The duration of washout will be adjusted to ensure that the C trough (observed plasma trough concentration at the 
end of a dosing interval) of TAK -788 at 168 hours postdose in Part 1 is <5% of the C max(maximum observed 
concentration) of TAK -788 at the dose used in the food effect evaluation. The planned washout period for Part 2 is 7 
days. PFTs and chest CT scan are required to be performed and assessed as normal at screening; PFTs must be 
performed no more than 7 days before Day 1. If pulmonary sym ptoms are reported, PFTs and a chest CT will be 
repeated 48 hours postdose before furlough. Other clinical study procedures are the same as those in the dose 
escalation phase. Cohort 4, 120 mg
n=8 (6 active, 2 placebo)
Cohort 1, 20 mg
n=8 (6 active, 2 placebo)Cohort 2, 40 mg
n=8 (6 active, 2 placebo)Cohort 3, 80 mg
n=8 (6 active, 2 placebo)Cohort 5,160 mg
n=8 (6 active, 2 placebo)Food effect with DiC (Part 2)
n=up to 16crossoverBioavailability DiC (Part 3)
n=up to 12 crossover
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 13of 92
Protocol Incorporating Amendment 03 13 November 2018
Part 3 –Bioavailability Study
Subjects will be randomly assigned to a crossover sequence at a 1:1 ratio and administered a single dose of 160 mg 
TAK -788 capsule A DiC (reference) or 160 mg TAK -788 capsule B DiC (test) on Day 1 in Period 1 and on Day 8 in 
Period 2 under fasting conditio ns, with a planned washout period of 7 days. PFTs (spirometry, lung volumes, and 
DLco) are required to be performed and assessed as normal at screening. PFTs will be performed on Day 3, Day 10, 
and/o r Early Termination visit in Part 3 only if indicated on the basis of pulmonary symptoms; no chest CT scans will 
be done. Other clinical study procedures are the same as those in the dose escalation phase. Subjects will have PK 
collection samples collected during confinement, and the last PK sample will be colle cted at 72 hours postdose in each 
period. Subjects will be furloughed after the last PK sample collection in Period 1. Subjects will return to the clinical 
study site on Day 7 for Period 2 study. Subjects will be released from the clinical study site after the last PK sample 
collection in Period 2. Safety phone conferences will occur on Day 15 and 30 days after the last dose (window of up to 
2 day s after Day 38).Study Schema for Food Effect Phase (Part 2)
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK-788 (formerly AP32788)
Study No. TAK-788-1001 Page 14 of 92Protocol Incorporating Amendment 03 13 November 2018
Study Schema for Relative Bioavailability Phase (Part 3)
Primary Objectives:
!Part 1: To assess safety and tolerability of TAK-788 and to identify a tolerable single oral dose of TAK-788 
administered as a drug-in-capsule (DiC) formulation in healthy subjects. 
!Part 2: To characterize the effect of a low-fat meal on the PK of TAK-788 administered as a DiC formulation in 
healthy subjects.
!Part 3: To evaluate the bioavailability of a test (Process B) DiC of TAK-788 relative to a reference (Process A) 
DiC of TAK-788 in healthy subjects.
Secondary Objectives:.
!Part 1: To characterize the PK of TAK-788 and its active metabolites, AP32960 and AP32914, administered as a 
DiC formulation in healthy subjects. 
!Part 2/Part 3: To assess the safety of TAK-788 following a single dose of TAK-788 in healthy subjects.
Exploratory Objectives:
!
!
Subject Population: Healthy subjects age d 18-55 years.
Number of Subjects:
Up to approximately 84 (approximately 56 in Part 1, up to 
16 in Part 2, and up to 12 in Part 3)Number of Sites: 
1
CCI
Property of T!!
ytyytyyytykeda: For non-commercial use only and subject to the applicable Terms of Usemsms
ility of TAity of T
le (DiC) f(DiC)
mmffect of a ect of a
e bioavailbioava
n healthy healthlu
ives:.es:.
haracteriharacter
mulation iulatio
2/Part 3:Part 3edno
ked
licable Te
bject tooooooooooooooooooooooooooooo the applic
seeeeeeeeee oooooooooooonnnnnnnnnnnnnnnlllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnddddddddddddddddddddddddddddddddddddddddddddddddddddddddddd subje
akoratory Oratory
f TakCCICCI
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 15of 92
Protocol Incorporating Amendment 03 13 November 2018
Dose Levels:
Part 1: Single rising dose starting at 20 mg, escalating to 
40, 80, 120, up to 160 mg. 
Part 2: A tolerable single dose identified in Part 1. 
Part 3: A 160 mg single dose DiC.Route of Administration:
Oral
Duration of Treatment:
One day (single dose) for Part 1, 2 days (2 single doses 
separated by ≥7-day washout) for each of Parts 2 and 3.Period of Evaluation:
Part 1: 30 days 
Part 2: 38 days
Part 3: 38 days
Main Criteria for Inclusion:
Aged 18 -55 years of age at the time of informed consent. 
Healthy  subjects defined as the absence of acute or chronic clinically significant deviations fr om normal in 
medical history, physical examination, electrocardiogram (ECG), and clinical laboratory determinations at 
screening. 
Body weight of ≥45 kg (women) or ≥55 kg (men) and a body mass index of 18.0 -30.0 kg/m2at screening. 
Normal baseline PFTs ( ≥80% of predicted normal for spirometry, lung volumes, and DLco) for Parts 1, 2 and 3; 
and chest CT scan at screening for Parts 1 and 2. 
Nonsmoker (never smoked or >20 years from last occurrence of smoking).
Normal organ function including hepatic, renal, and bone marrow function (please refer to study reference manual 
or site manual for normal ranges). 
Main Criteria for Exclusion:
Medical History and Concurrent Diseases
–Ongoing or prior pulmonary disease including asthma, chronic obstructive pulmonary disease, interstitial 
lung disease, and pneumonitis including but not limited to drug -related pneumonitis. 
–Any history  of cardiovascular disease including a history of cong enital prolonged QT syndrome or 
unexplained cardiac arrest.
–Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown 
other reason that may alter the PK of TAK -788.
–Pulmonary infection ongoing or within 30 da ys of informed consent.
–Current o r recent (within 3 months) GI disease.
–Any major surgery  within 4 weeks before study drug administration.
–Blood transfusion within 4 weeks before study drug administration. 
–Histor y of bleeding disorder.
–Inability to tolera te oral medication. 
–Inability to undergo venipuncture and/or tolerate venous access. 
–Inability to tolerate multiple blood sampling. 
–Ongoing or active infection, including but not limited to, the requirement for intravenous antibiotics. 
–Positive serolog y or a known history of hepatitis B virus, hepatitis C virus, and HIV. 
Physical and Laboratory Test Findings
–Any clinically  significant abnormality at screening of cardiac, hepatic, renal, respiratory, GI, endocrine, 
immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
–Resting blood pressure >140/90 mmHg at screening (a single repeat measurement is allowed if the initial 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 16of 92
Protocol Incorporating Amendment 03 13 November 2018
measurement is outside these limits).
–Resting pulse rate <45 beats per minute.
Allergies and Adverse Dr ug Reactions
–Histor y of severe allergy/hypersensitivity reaction or ongoing allergy/hypersensitivity reaction, as judged by 
the investigator, or history of hypersensitivity to epidermal growth factor receptor/human epidermal growth 
factor receptor 2 inhibi tors. 
Prohibited Treatments and Therapies 
–Prior exposure to TAK -788.
–Exposure to any small molecular drug treatment, including investigational small molecular drugs, within 
4weeks or biologic drug treatment, including investigational biologics, within 1 6weeks before study drug 
administration. 
–Use of any prescription or over -the-counter (OTC) stomach acid controllers within 2 weeks before study drug 
administration.
–Use of any  other drugs, including OTC medications, nutritional supplements, and herbal pr eparations 
(including St. John’s wort) within 1 week before study drug administration (except occasional use of 
acetaminophen and ibuprofen which are allowed up to 24 hours before dosing). 
–Consumption of any food or beverages containing grapefruit, Sevill e oranges, blood oranges, or 
pomegranates within 1 week before study drug administration.
Endpoints:
Primary : 
–Part 1: safety profile of orally administered TAK -788. 
– Number and percentage of subjects with 1 or more AE.
– Number and percentage of subjects with 1 o r more serious AE.
– Number and percentage of subjects with clinically defined abnormal laboratory values.
– Number and percentage of subjects with clinically defined abnormal vital signs.
–Part 2: summary statistics of the PK parameters for TAK -788 und er fasted conditions or following a low -fat 
meal. 
– C max.
– t max(time of first occurrence of C max).
– AUC t(area under the concentration -time curve [AUC] from time 0 to time t).
– AUC ∞(AUC from time 0 to infinity calculated using the last quantifiable concentra tion.
– t 1/2z: terminal disposition phase half -life.
–Part 3: summary statistics of the PK parameters for TAK -788 in different DiC under fasted conditions. 
– C max.
– t max.
– AUC t.
– AUC ∞ (if data permitted) .
– t 1/2z.
Secondary: 
–Part 1: summary statistics of the PK pa rameters for TAK -788 and its 2 active metabolites, AP32960 and 
AP32914 under fasted conditions. 
– C max.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 17 of 92
Protocol Incorporating Amendment 03 13 November 2018
– tmax.
– AUC t.
– AUC ∞.
–t 1/2z.
– Part 2: safety profile of TAK-788 under fasted conditions or following a low-fat meal. 
– Part 3: safety profile of TAK-788 under fasted conditions.
!Exploratory: 
Statistical Considerations:
Pharmacokinetic AnalysesDescriptive statistics, including mean, SD, coefficient of variation (%CV), minimum, median, and maximum, will be 
calculated and presented by dose level in Part 1,for each treatment under fasted versus fed conditions in Part 2, and for the test versus reference treatments in Part 3 for plasma concentrations of TAK-788 and its 2 active metabolites.
Analysis of PK parameters will be per formed for TAK -788 and its 2 active metabolites. The concentration versus time 
profiles will be analyzed via non-compartmental methods to estimate PK parameters in plasma. Descriptive statistics 
(number of observations, arithmetic mean, geometric mean, SD, %CV, median, minimum, and maximum values) will be presented for the PK parameters (C
max, tmax, AUC t, AUC ∞, t1/2z, AUC extrap% (area under the curve from the last 
quantifiable concentration to infinity calculated using the observed value of the last quantifiable concentration, expressed as a percentage of AUC
∞), CL/F (apparent clearance after extravascular administration, calculated using the 
observed value of the last quantifiable concentration), V z/F (apparent volume of distribution during the terminal 
disposition phase after extravascular administration, calculated using the observed value of the last quantifiable concentration), . 
In Part 2, PK parameters (natural log-transformed [ln]) of TAK-788 will be compared under fasted versus fed 
conditions using an analysis of variance (ANOVA) model. The ANOVA model will include fasted versus fed condition, peri od, and sequence as fixed effects and subject nested within sequence as a random effect. Each ANOVA 
will calculate the least-squares mean (LSM), the difference between treatment LSMs, and the SE associated with the difference. Residual, subject nested within sequence, and intersubject variance, along with the intrasubject and intersubject CV, will be reported. Ratios of LSM will be calculated using the exponential function of the difference between treatment LSMs from the analyses on the ln-transformed C
max, AUC t, and AUC ∞.
In Part 3, PK parameters (ln-transformed) of TAK-788 for the test formulation (Process B DiC) and the reference 
formulation (Process A DiC) will be compared using an ANOVA model. The ANOVA model will include treatment CCI
Property of Takeda: For non-commercial an, SD, con, SD, c
level in Pevel in
ments in Pents in
s will be pwill be
d via nonvia no
ions, arithns, arit
he PK pahe PK
oncentraticentra
s a percens a perce
value of value o
sition phaition ph
ncentrationcentrati
In Part 2n Part
conditcondal u
conal
ycable Terms of Usemsms
tyl use only and subject to the applica
CCI
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 18of 92
Protocol Incorporating Amendment 03 13 November 2018
(test versus reference), period, and sequence as fixed effects and subject nested within sequence as a random effect. 
Each ANOVA will calculate the LSM, the difference between treatment LSMs, and the SE associated with the 
difference. Residual, subject nested within sequence, and intersubject variance, along with the intrasubject and 
intersubject CV, will be reported. Ratios of LSM will be calculated using the exponential function of the difference 
between treatment LSMs from the analyses on the ln -transformed C max, AUC t, and AUC ∞(if data permitted).
Safety Analyses
Safety assessments will include AEs, vital signs, ECGs, physical examinations, clinical laboratory tests, P FTs, from 
Parts 1, 2, and 3; and chest CT scan for Parts 1 and 2. The incidence of AEs will be tabulated and reviewed for clinical 
significance. 
Safety and tolerability parameters will be listed by subject, study group, and treatment group, and displayed in 
summary tables using descriptive statistics. All subjects receiving placebo in Part 1 will be pooled and analyzed as one 
placebo group. Original terms used in the electronic case report forms by the investigator or designees to identify AEs 
will be code d using Medical Dictionary for Regulatory Activities (version 20.0 or higher) terminology. 
Sample Size Justification: 
Part 1: The sample size is determined based on clinical rather than statistical considerations. The number of 
subjects in this part of study  is consistent with phase 1 dose -finding studies.
Part 2: With a sample size of 14 healthy subjects, the 90% confidence interval for the AUC ratio is expected to be 
in the range of 84% to 119%, using an intrasubject AUC variability of 27% in cancer pa tients and assuming a 
TAK -788 AUC ratio of 1 in the fed versus fasted comparison. After accounting for 2 potential dropouts in Part 2, 
the final sample size is up to 16 healthy subjects. This sample size assumes no replacement of subjects who may 
drop out of the study before the completing the PK sample collections in Part 2.
Part 3: With a sample size of 10 healthy subjects, the 90% confidence interval for the C maxratio is expected to be 
in the range of 87% to 115%, using an intrasubject C maxvariability of 17% estimated in healthy subjects. After 
accounting for 2 potential dropouts in Part 3, the final sample size is up to 12 healthy subjects. This sample size 
assumes no replacement of subjects who may drop out of the study before the complet ing the PK sample 
collections in Parts 3
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 19of 92
Protocol Incorporating Amendment 03 13 November 2018
3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
clinical study supplier list or equivalent. The ident ified vendors for specific study -related activit ies 
will perform these act ivities in full or in partner ship wi th the sponsor. 
3.2 Principal Investigator/Coordinating Investigator
Takeda will select a signatory  coordinat ing invest igator from the invest igators who participate in 
the study . Selection criteria for thi s investi gator will include significant knowled ge of the study  
protocol , the study  medicat ion, thei r experti se in the therapeutic area and the conduct of clinical 
research and study  parti cipat ion. The signatory  coordinating investigator will be required to 
review and sign the clinical study report and by doing so agrees that it accurately describes the 
resul ts of the study . 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 20of 92
Protocol Incorporating Amendment 03 13 November 2018
3.3 List of Abbreviations
-hCG -human chorionic gonadotropin
AE adverse event
ANOVA analy sis of variance
API active pharmaceutical ingredient
AUC area under the plasma concentrati on-time curve
AUC 24 area under the plasma concentration -time curve from time 0 to 24 hours
AUC extrap% area under the curve from the last quantifiable concentration to infinity calculated using 
the observed value of the last quantifiable concentration, expressed as a percentage of 
AUC ∞
AUC t area under the concentration -time curve from time 0 to time t
AUC ∞ area under the concentration -time curve from time 0 to infinity, calculated using the 
observed value of the last quantifiable concentration
Cav average plasma concentration
CFR Code of Federal Regulations
Cmax maximum observed plasma concentration
CNS central nervous system
CRO contract research organization
CT computed tomography
Ctrough observed plasma concentration at the end of a dosing interval
CV coefficient of variation
DiC drug-in-capsule (formulation)
DLco diffusion capacity
DLT dose-limiting toxicity
ECG electrocardiogram
eCRF electronic case report form
EGFR epidermal growth factor receptor
FDA Food and Drug Administration
FIH first-in-human
GCP Good Clinical Practice
GI gastrointestinal
GLP Good Laboratory Practice
HBV hepatitis B virus
HCV hepatitis C virus
HER2 human epidermal growth factor 2
IB investigator’s brochure
ICF informed consent form
ICH International Conference on Harmonisation
IEC independent ethics committee
IRB institutional review board
IV intravenous
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 21of 92
Protocol Incorporating Amendment 03 13 November 2018
ln natural log -transformed
LSM least-squares mean
MedDRA Medical Dictionary for Regulatory Activities
MTD maximum tolerated dose
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
NSCLC non–small -cell lung cancer
NOAEL no-observed -adverse -effect level
OTC over-the-counter
PFT pulmo nary function test
PK pharmacokinetic(s)
PO per os (oral)
PTE pretreatment event
QD quaque die (once daily)
RP2D recommended phase 2 dose
SAE serious adverse event
SOP standard operating procedure
SUSAR suspected unexpected serious adverse reaction
t1/2z terminal disposition phase half -life
TEAE treatment -emergent adverse event
TKI tyrosine kinase inhibitor
tmax time to first occurrence of C max
UK United Kingdom
US United States
WHO World Health Organization
WT wild ty pe
3.4 Corporate Identification 
Millennium Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda 
Pharmaceutical Company Limited
TDC Japan Takeda Development Center Japan
TDC Asia Takeda Development Center Asia ,Pte Ltd
TDC Europe Takeda Development Centre Europe Ltd
TDC Americas Takeda Development Center Americas , Inc
TDC TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Takeda Millennium Pharmaceuticals, Inc, TDC Japan, TDC Asia, TDC Europe and/or TDC 
Americas, as applicable
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 22of 92
Protocol Incorporating Amendment 03 13 November 2018
4.0 INTRODUCTION
4.1 Scientific Background
Specific genetic lesio ns that drive the prolifer ation of cancer cells, such as those result ing in 
activat ion of certain ty rosine kinases, render many cancers highly sensit ive to therapeutic agents 
that inhibit the affected kinase (eg, ty rosine kinase inhibitors [TKIs]). These include activating 
mutati ons in the epidermal growth factor receptor (EGFR), which have been ident ified in 21% to 
40% of patients with non –small -cell lung cancer (NSCLC) [ 1,2]. There are mult iple classes of 
activat ing mutations in EGFR that vary  widely  in their degree of sensit ivity to available TKIs. 
Because inhibit ion of wild-type (WT) EGFR in normal t issues is associated with dose limit ing 
toxicities (DLTs), substantial clinical benefit has generally  been associated wi th TKIs that inhibit 
specific, act ivated variants of EGFR more potently than they inhibit WT EGFR.
The m ost comm on activating mutations in EGFR are in -frame delet ions in exon 19 and a 
Leu858Arg (L858R) substitution in exon 21, together account ing for approximately  90% of  all 
EGFR activatin g mutati ons [
3]. Erlotinib and gefit inib (“first generation” EGFR TKIs), and 
afat
inib (a second -generat ion EGFR TKI), potentl y inhibit these mutants in vitro and induce high 
response rates of approximately 60% to 70% in patients with these mutations [4]. Although these 
TKIs are approved for use in pat ients with these specific m utations, thei r clinical efficacy is 
ultimately limited by the development of resistance, such as by mutation of the EGFR kinase 
domain gatekeeper residue (T790M), which occurs in 50% of patients [
5,6]. Recent ly, osimert inib 
was approved for treatm ent of  patients wi th metastati c EGFR T 790M m utation-positive NSCLC, 
whose disease has progressed on or after EGFR TKI therapy . 
For erl otinib and gefit inib, high response rates have largely been restricted to patients with the 
most comm on activating mutants; however, preliminary  resul ts wi th afatinib suggest that 
relatively high response rates are also achieved in patients with a second class of activating 
mutants, so -called “uncommo n” m utants, such as those occurring at other amino acids in 
exons 19and 21 (eg, G719 and L861) [7]. 
The final class of EGFR act ivating mutations, known as exon 20 insert ions, accounts for 
approximately  9% of  EGFR mutant NSCLC [
8]. Unlike mutations in exons 19 or 21, almo st all 
EGFR exon 20 insertions confer in vitro and primary  clinical resistance to the 3 approved EGFR 
TKIs [
7,9,10] . Patients with NSCLC containing EGFR exon 20 insert ions exhibit clinical 
characterist ics similar to those carrying commo n EGFR mutations [
11](eg, y oung, nonsmoker, 
with adenocarcinom a subt ype), consistent with potent ial roles as driver m utations that coul d 
confer benefit to targeted therapy. In summary, while erlotinib, gefit inib, and af atinib are approved 
for use in NSCLC pat ients with co mmo n act ivating mutations in EGFR (ie, exon 19 delet ions and 
L858R subst itutions), no therapies are approved for patients with EGFR exon 20 insert ions. 
Hum an epidermal growth factor 2 (HER2) mutations, typically consist ing of in -frame insertions in 
exon 20, have also been ident ified as potential oncogenic drivers in 2% to 4% of patients with 
NSCLC. These pat ients exhibit clinical characteristics similar t o pati ents wi th EGFR m utations 
[
12-14] . Currently , no therapi es are approved for use in NSCLC patients with HER2 activat ing 
mutati ons.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 23of 92
Protocol Incorporating Amendment 03 13 November 2018
TAK -788 i s an orally administered small mo lecule TKI and was specifically designed to address 
the unmet medical need in the subset of NSCLC patients for whom no target therapy  is available. 
This patient populat ion includes, but is not limited to, patients whose tumors harbor EGFR exon 
20 insertion mutations, HER2 exon 20 insert ion mutations. In nonclinical studies, TAK -788 
potently  inhibi ted all  activated forms of EGFR tested, including those containing exon 20 
activat ing insertions, other uncommo n activating mutations, and the co mmo n act ivating mutations 
(exon 19 delet ions and L858R) with or without the T790M resistance mut ation. TAK -788 also 
potently inhibit s HER2 activated by exon 20 insertio ns and po int mutations, and by amplification. 
TAK -788 inhibits all of these variants more potently than it inhibits WT EGFR, suggesting it may 
have the select ivity necessary  to achi evelevels of exposure required to inhibit all act ivated forms 
of these kinases [8,9,11-14] . A first -in-human (FIH) phase 1/2 study  of TAK - 788 
(AP32788 -15-101) i s ongoing wi th the m ain objectives of determining the safet y profile, 
ident ifying reco mmended phase 2 dose (RP2D) and dose -limiting toxicit ies (DLTs) of TAK -788, 
characteri zing the pharmacokinet ic (PK) of TAK -788, and evaluat ing the ant itumor activit y of 
TAK -788 in NSCLC pat ients with EGFR or HER2 mutations. 
4.2 Nonclinical Experience
Refer to the IB. 
4.3 Clinical Experience
An FIH phase 1/2 study  in pat ients with NSCLC ( AP32788 -
15-101) is ongoing. As of the 
08September 2017 data cut -off, a total of 34 pat ients have been treated with 6 different once -daily 
(QD) doses evaluated. Two DLTs were observed and reported in the current dose escalat ion 
cohorts, 1 each at 80 mg (Gr ade 3 pneumonit is) and 120 mg (Grade 5 pneumonit is). Of the 
33patients included in the clinical database reports, 21 patients (63.6%) had EGFR exon 20 
inserti on m utations, and 4 pati ents (12.1%) had HER2 exon 20 insertions or point mutations. 
Preliminary PK data suggest that TAK -788 was absorbed into systemic circulat ion with tmax
(median time to first occurrence of the maximum observed plasma concentration [C max]) ranging 
from 4-6 hours fo llowing oral  (PO) administration of repeated daily  doses of  TAK - 788. The 
steady -state PK of TAK -788 was achieved wit hin 1 week of TAK -788 treatment. Steady -state area 
under the plasma concentration -time curve (AUC) fro m time 0 to 24 hours (AUC 24) of TAK -
788 
increased in approximately dose -proporti onally at doses ranging from 5-180 m g. Administrati on 
of TAK -788 PO QD resulted in approximately 50% accumulation in AUC 24. The effect ive 
half-life based on accumulat ion was approximately 16 hours (range, 6 -28 hours). 
The clinical safet y data available indicated no particular sa fety findings that are unique compared 
with other EGFR TKIs. Diarrhea (33.3%) was the most commo n treatment -
related adverse event 
(AE) and was the only  Medical Dict ionary for Regul atory  Activities (MedDRA) Preferred Term 
occurring in ≥20% of patients treat ed with TAK -788. Rash, which is co mmo nly observed wit h 
other EGFR TKIs, was also observed with TAK -788 (12.1% of all patients).
Preliminary efficacy data showed 2 confirmed PRs and 1 PR awaiting confirmat ion in a total of 
8patients who had at least 1 dise ase assessment following treatment with TAK 788 at 80 mg QD 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 24of 92
Protocol Incorporating Amendment 03 13 November 2018
and 120 mg QD, respectively. All pat ients who responded to treatment with TAK -788 had EGFR 
exon 20 insertion mutations.
In mid -January 2018, 160 mg QD was ident ified as the maximum tolerated dose (MTD) and was 
the RP2D for the phase 2 expansio n cohorts which include 4 histologically  and m olecularly  
defined cohorts targeting patients with NSCLC containing: (1) EGFR exon 20 insertions without 
active, measurable central nervous system (CNS) metastases , (2) HER2 exon 20 insertions or point  
mutati ons wi thout active, measurable CNS metastases, (3) EGFR exon 20 insertions or HER2 
exon 20 insertions or point mutations with active, measurable CNS metastases, and (4) other 
targets against which TAK -788 is act ive, wi th or wit hout CNS metastases. 
In summary, TAK -788 was generally well -tolerated, and preliminary  anticancer activit y was 
observed in EGFR exon 20 insert ion-positive NSCLC patients who had been previously treated. 
4.4 Rationale for the Proposed Study
This study  is proposed to characterize safety  and tol erabili ty of a single oral dose of TAK -788, to 
ident ify a safe and tolerable dose of TAK -788 administered as a drug-in-capsule (DiC) 
formulationin healt hy subjects , to eval uate the effects of a low -fat meal on the PK of TAK -788 
and its act ive metabolites AP32960 and AP32916, and to assess the relat ive bioavailabilit y of 
2DiCs of TAK -788. Part 1 of the study  will use a rando mized, double -blind, placebo -controlled, 
single rising dose escalation design to determine the safet y and tol erabili ty of TAK -788 and 
characterize the PK o f TAK -788 and its active metabo lites, and to i dentify a tolerable single dose 
in healthy subjects. Part 2 of the study  will assess the effects of a low -fat meal on the PK of 
TAK -788 administered as a DiC formulat ion. Part 3 of the study  will evaluate the rel ative 
bioavailabilit y of a single dose of TAK -788 160 mg Process B DiC (test) versus a single dose of 
TAK -788 160 m g Process A DiC (reference).
4.4.1 Risk -Benefit Assessment
The availabl e information suggests that the present clinical study  has an acceptable benefit -risk 
profile. 
The inclusio n and exclusio n criteria and safet y monitoring practices employed by this protocol are 
adequate to protect the subjects’ safet y and should detect al l expected treatment -emergent adverse 
events (TEAEs).
There will be no direct healt h benefit for trial participants from receipt of study  drug. An indirect 
healt h benefit to the subjects enro lled in this trial is the free medical tests received at screening and 
during the study .
4.4.2 Rationale for Single Dose Escalation (Part 1)
This is the first single -dose experience wit h TAK -788 in healt hy subjects. In this double -blind, 
rando mized, placebo -controlled study, the safet y, tolerabilit y, and PK of TAK -788 and its 2active 
metabo lites, AP32940 and AP32916, will be evaluated. Addit ionally , a tol erable single dose will 
be ident ified for future clinical  pharmacol ogy studies in healt hy subjects.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 25of 92
Protocol Incorporating Amendment 03 13 November 2018
The starting dose of 20 mg for healt hy subjects i s based on clinical safet y/tolerabilit y data from 
phase 1 study  (AP32788-15- 101) in cancer patients and is supported by  nonclinical safet y data. 
The phase 1 clinical study (AP32788 -15-101) investigat ing the safet y and PK of repeated doses of 
TAK -788 in patients with NSCLC started at 5 mg QD. At the time of first data cut -off in 
September 2017, the 120 -mg QD dose was being tested. No Grade ≥2 treatment -related AEs were 
reported within 3 days o f the repeated treatment in any pat ient. 
In a 28 -day Good Laboratory  Practi ce (GLP)
-compl iant repeat -dose study  in dogs (Report 
WIL-69513), a single dose of 1 mg/kg is considered to be the no -observed -adverse -effect level 
(NOAEL). The C av(mean total  average plasma concentration) of TAK -788 and its metabolites 
was 44.7 nM, which was ~4 fo ld the mean total  Cav(12.6 nM) fo llowing a single dose 20 mg 
TAK -788 in cancer patients (data on file). Addit ionally , there were no TAK -788–related effects on 
the cardiovascular, respiratory  and CNS (on the basis of monitoring in repeat -dose GLP toxicit y 
studi es), TAK -788 was neither a potent hERG inhibitor, and TAK -788 was neither mutagenic nor 
clastogeni c in GLP -compliant bacterial reverse mutation assays (Report 9601435) and in in vitro
mammalian chromoso me aberration assays (Report 9601436). Therefore, the nonclinical safet y 
data supports a single clinical starting dose of 20 mg. 
The starting dose of TAK -788 in this study  will be a single dose of 20 mg and the dose escalat ion 
steps will be similar to those in study  AP32788 -
15-101. The highest dose tested in the dose 
escalat ion phase will not exceed the unit dose of MTD ident ified in Study AP32788
-15-101.
The aim of Part 1 of this protocol is to determine the single -dose safet y and tol erabili ty of 
TAK -788 administered as DiC in healt hy subjects. The dose in P art 1 of this study  may be 
escalated up to 160 mg. The dose escalat ion decisions in Part 1 of the study  will be gui ded by  
safet y/tolerabili ty data in previ ous cohorts as outlined in Sect ion 8.3.
4.4.3 Rationale for Food Interaction (Part 2)
Typically , a clinical study  in healt hy subjects may provide a more accurate estimate of food effect  
on drug PK than a study  in patients. 
Inform ation on t he effects offood ingest ion on T AK-788 PKwill provide meal int ake instruct ions 
when TAK -788 is administered to pati ents in future clinical studies. Food canaffect oral
bioavailabilit yvia various mechanisms, including altering gastric emptying rate, stimulating bile 
flow,altering gastrointest inal(GI) pH, increasing splanchnic blood flow, changing the luminal
metabolism of drug substances, and physically or chemically interacting withdrug substance or 
dosage form.
Food interaction is generally greatest when drug is administered shortly after food has been
ingested. Inaddit ion, the nutritional and caloric content of food, volume of food, and temperature
mayalso playaroleinfood-drug interactions and it is generally accepted that food thatis high in 
calories and fat represents aworst -case scenario for this assessment. However, several recently 
approved oral EGFR TKIs and ALK+ inhibitors were also studied with a standard meal or a 
low-fat and low -calorie meal for patients with cancer who are receiving routine oral
administration of these drugs [
15,16] . If possible, food effects assessments are preferably 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 26 of 92
Protocol Incorporating Amendment 03 13 November 2018
conducted on the to-be-marketed formulation o f a drug to avoid having to reassess food- drug 
interactions because of formulation changes. However, timely evaluation of food-drug interactions 
will provide important information on dos ing conditions in future clinical trials. 
In vitro, neither high-fat nor low-fat meals appear to increase or decrease TAK-788 absorption in a 
perfusion chamber study at 2 relevant clinical doses of 120 and 180 mg (data on file). Therefore, a 
low-fat meal is not expected to increase bioavailability. 
Because TAK-788 is a Biophar maceutics Classification System class 2 compound, there is a 
possibility that the magnitude of the food eff ect can be dose-dependent. Accordingly, it is 
important to conduct the food effect evaluation at or near the unit dose of the RP2D regimen. The 
dose used in the food effect study will be the unit doses determined in Part 1 of this study in 
healthy sub jects to be safe and tolerable. 
Since the DiC formulation will be used in the planned phase 2 pivo tal clinical study, this portion of 
the study will be conducted with DiC of TAK-788. This part of the study will evaluate the effects
of low-fat and low-calorie meal on the PK of TAK-788 administered as DiC. 
4.4.4 Rationale for R elative Bioavailability Assessment (Part 3)
Process A and Process B TAK-788 drug substance (succinate salt) are chemically identical but are 
synthesized by different synthetic routes. The physiochemical properties of Process A and Process 
B TAK-788 drug substance are, however, different. The API powder prepared via Process B has 
larger primary particles, lower specific surface area, and a higher bulk density than the API powder 
prepared via Process A. The rationale for Part 3 of the study is to perform relative bioavailability 
assessment of Process B versus Process A DiC to enable PK bridging across the patients who are 
using or will be using these 2 DiCs in the TAK-788 clinical development program.
 CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Useon in a n in a 
erefore, refore
d, there id, there
dingly, iingly
e RP2D RP2D
art 1 of tht 1 of 
otal clinical clin
f the studf the stu
inisterednistere
ment (Pent (
(succinasucci
hysysioiochec
fferent. Trent.
face areaace a
for Part 3or Part
essessA DA
Cs in thein th
mercmm
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 27 of 92
Protocol Incorporating Amendment 03 13 November 2018
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objectives
The primary objectives are: 
Part 1: To assess safety and tolerability of TAK-788 and to identify a tolerable single oral dose of
TAK-788 administered as a drug-in-capsule (DiC) formulation in h ealthy sub jects. 
Part 2: To characterize the effect of a low-fat meal on the PK of TAK-788 administered as a DiC 
formulation in healthy subjects.
Part 3: To evaluate the bioavailability of a tes t (Process B) DiC of TA K-788 relative to a 
reference (Process A) DiC of TAK-788 in healthy subjects.
5.1.2 Secondary Objectives
The secondary objectives are: 
Part 1: To characterize the PK of TAK-788 and its active metabolites, AP32960 and AP32914, 
administered as a DiC formulation in healthy subjects. 
Part 2/ Part 3: To assess the safety of TA K-788 following a single dose of TAK-788 in healthy 
subjects.
5.1.3 Exploratory Objectives
The exploratory objective is: 
5.2 Endpoints
5.2.1 Primary Endpoints
The primary endpoints are: Part 1: safety profile of orally administered TAK-788. 
!number and percentage of subjects with 1 or more AEs.
!number and percentage of subjects with 1 or more SAEs.
!number and percentage of subjects with clinically defined abnormal laboratory values.
!number and percentage of subjects with clinically defined abnormal vital signs.CCI
Property of Takeda: For npointsoints
Primaryrima
e primarye prima
Part Pa 1:1of!lol
mercial use only and subject to the applicable Terms of Usegle oral gle ora
hy subjehy subj
adminisdminis
TAKAK-787
ts.s.
active mctive
allthy subthy sull
88 f8 fololffff
r non-comme
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 28 of 92
Protocol Incorporating Amendment 03 13 November 2018
Part 2: summary statistics of the PK parameters for TAK-788 under fasted conditions or following 
a low-fat meal.
!Cmax.
!tmax.
!AUC t(area under the concentration-time curve from time 0 to time t).
!AUC∞(area under the first moment concentration-time  curve from time 0 to  infinity calculated 
using the last quantifiable concentration.
!t1/2z(terminal disposition phase half-life).
Part 3: summary statistics of the PK parameters for TAK-788 with different DiC under fasted 
conditions. 
!Cmax.
!tmax.
!AUC t.
!AUC∞(if data permitted).
!t1/2z.
5.2.2 Secondary Endpoints
The secondary endpoints are: Part 1: summary statistics of the PK parameters for TAK-788 and its 2 active metabolites,
AP32960 and AP32914 under fasted conditions. 
!Cmax.
!tmax.
!AUC t.
!AUC∞.
!t1/2z.
Part 2: safety profile of TAK-788 under fas ted conditions or following a low-fat meal.
Part 3: safety profile of TAK-788 under fasted conditions.
5.2.3 Exploratory Endpoints
The exploratory endpoint is: 
CCI Property of Takeda: For non-commercial use only and subject to the applicable Terms of Usefinitfinity cay c
fferent Drent 
e PK parPK pa
14 unde4 und
rt 2:rt 2: safsTa
Part Paryo
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 29 of 92
Protocol Incorporating Amendment 03 13 November 2018
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Usenly and subject to the applicable Terms o
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 30of 92
Protocol Incorporating Amendment 03 13 November 2018
6.0 STUDY DESIGN
This is a rando mized, doubl e-blind, placebo -controlled single rising dose study, fo llowed by an 
open -label, crossover evaluat ion of the effects of a low -fat meal on the PK of TAK -788 and its 
2active metabo lites in heal thy subjects, and a crossover evaluat ion of the relat ive bioavailabilit y 
of TAK -788 Process B DiC (test) versus Process A DiC (reference) in healt hy subjects under 
fasting condit ions. Fo llowing the co mpletion o f Part 1 (dose escalat ion phase) where a safe and 
tolerable dose in healt hy subjects will be ident ified, Part 2 (food effect phase) and Part 3 (relat ive 
bioavailabilit y of TAK -788 capsules) will be init iated where the effects of a low -fat meal on 
TAK -788 and the relat ive bioavailabilit y of TAK -788 in test versus reference will be studied.
6.1 Overview of Study De sign
6.1.1 Part 1 –Dose Escalation
The purpose of Part 1 of the study  is to assess the safet y and tol erabili ty of TAK -788 and to 
ident ify a tolerable single dose. A single dose escalation design will be used, as detailed in 
Secti on8.3. 
In the doubl e-blind, rando mized, placebo -controlled dose escalat ion phase, cohorts of 8 healt hy 
subjects will be rando mized: Under fasting condit ions, 6 subjects will rece ive a single dose of 
TAK -788 and 2 subjects will receive placebo. The starting dose will be 20 mg, then with each 
subsequent 8- subject cohort the dose will escalate to a single dose of 40, 80, 120, up to 160 mg. 
Dose escalat ion can occur if there are no DL Ts fo llowing the administration of TAK -788 and all 
Grade ≥2 treatment -related AEs resolve to Grade ≤1 or return to baseline by Day 5. If all 
treatm ent-related Grade ≥2 AEs have not resolved to Grade ≤1 or returned to baseline by Day 5, 
the assessment will be repeated on Day  8and Day 15, if necessary , before proceeding to the next 
planned higher dose. The subjects will remain at the clinical study  site for at least 48 hours 
postdose for close safet y monitoring. The subjects will be furloughed fro m the site 48 hours 
postdose if there are no Grade ≥2 AEs. Subjects will return to the site for PK sample co llection on 
Days 4, 5, and 8. A fina l safet y phone conference will occur 30 days after the last dose ( window of 
up to 2 days after Day 30). 
Addit ional cohorts may also be enro lled in Part 1 to assess the safet y, tolerabili ty, and PK of 
single- dose TAK -788 Di C containing TAK -788 active pharm aceut ical ingredient (API) from a 
different synthet ic process (such as Process A). The dose(s) of TAK -788 in the addit ional
cohort(s) will be determined by the safet y, tolerabilit y, and PK exposure data from the completed 
cohorts in this study  and the experience in the ongoing phase 1/2 study  in pat ients with NSCLC 
(Study  AP32788 -15-101). The highest dose tested in Part 1 of t he study will not exceed the unit 
dose of the MTD identified in Study  AP32788 -
15-101.
To mit igate the risk of treatment, pulmo nary function tests (PFTs: spirometry, lung vo lumes, and 
diffusio n capacit y [DLco]) and chest computed tomography  (CT) scan are re quired to be 
perform ed and assessed to be normal (PFTs ≥80% of predicted normal) at screening no more than 
7 day s before Day  1. At 48 hours postdose before furlough, PFTs will be performed and 
pulmo nary symptoms assessed. If the DLco has decreased by >20% from baseline or the subject 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 31of 92
Protocol Incorporating Amendment 03 13 November 2018
reports pulmo nary symptom s on Day  3, a chest CT scan will be performed. Any DLco 
abnorm alities or chest CT scan abnormalit ies will be fo llowed weekly unt il reso lution. An 
appropriate treatment will be init iated by the investiga tor or attending pulmo nologist in the event 
of clinically significant pulmo nary symptoms, abnorm al DLco, or abnorm al chest CT scan.
Figure 6.a Dose Escalation Schema (Part 1)
Abbreviations: DiC, drug- in-capsule. 
6.1.2 Part 2 –Food Effect
The purpose of Part 2 is to evaluate the effect of a low -fat meal on TAK -788 PK using a 2- way 
crossover design. The dose used will be a tolerable single dose identified in Part 1. 
In the food effects part of the study , subj ects will be randomized to a crossover sequence at a 
1:1ratio and administered the tolerable single dose on Day  1 in Peri od 1 and Day  8 in Peri od 2 
with a low-fat m eal (Treatm ent A) or under fast ing conditions (Treatment B) with a planned 
washout period o f at least 7 day s which may  be updated pending the PK results from Part 1. The 
content of a low-fat meal is shown in Table 8.a. The duration of washou t will be adjusted to ensure 
that the C trough (observed plasma trough concentration) of TAK -788 at 168 hours postdose in Part 1 
is <5% of the observed C maxof TAK -788 at the dose of the food effect evaluation. The planned 
washout period used in Part 2 is 7 days. PFTs (spirometry , lung vo lumes, and DLco) and chest CT 
scan are required to be performed and be assessed as normal at screening. PFTs and chest CT scan 
will be done on Day  3, Day  10, and/or Early Terminat ion visit in Part 2 only if indicated on the 
basis of pulmo nary symptom s. Other clinical study procedures are the same as those in the dose 
escalat ion phase. Subjects will return to the site for the PK sample co llection on Day s4, 5, 8, 11, 
12, and 15. A final safet y phone conference will occur 30 da ys after the last dose ( window of up to 
2days after Day 38). Cohort 4, 120 mg
n=8 (6 active, 2 placebo)
Cohort 1, 20 mg
n=8 (6 active, 2 placebo)Cohort 2, 40 mg
n=8 (6 active, 2 placebo)Cohort 3, 80 mg
n=8 (6 active, 2 placebo)Cohort 5,160 mg
n=8 (6 active, 2 placebo)Food effect with DiC (Part 2)
n=up to 16crossoverBioavailability DiC (Part 3)
n=up to 12 crossover
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 32of 92
Protocol Incorporating Amendment 03 13 November 2018
Figure 6.b Food Effect Schema (Part 2)
6.1.3 Part 3 –Relative Bioavailability
The purpose of Part 3 is to evaluate the bioavailabilit y of a test Di C of TAK -788 relative to a 
reference DiC of TAK -788. Part 3 of the study  will be open -label. 
Subjects will be rando mly assigned to a crossover sequence at a 1:1 ratio and administered a single 
dose of 160 mg TAK -788 capsule A DiC (reference) or 160 mg TAK -788 capsule B DiC (test) on 
Day 1 in Peri od 1 and on Day  8 in Peri od 2 under fasting condit ions, with a planned washout 
period of  7 day s. PFTs (spi rometry, lung vo lumes, and DLco) are re quired to be performed and 
assessed as normal at screening. PFTs will be performed on Day 3, Day 10, and Early Terminat ion 
visit in Part 3 only if indicated on the basis o f pulmo nary symptoms; no chest CT scans will be 
done. Other clinical study  procedures are the same as those in the dose escalat ion phase. Subjects 
will have PK co llection samples co llected during confinement, and the last PK sample will be 
collected at 72 hours postdose in each period. Subjects will be furloughed after the last PK sample 
collect ion in Period 1. Subjects will return to the clinical study site on Day 7 for Period 2 study. 
Subjects will be released fro m the clinical study site after the last PK sample collection in Period 2. 
Safety phone conferences will occur on Day 15 and 30 days after the last dose (window of up to 2 
days after Day  38).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 33of 92
Protocol Incorporating Amendment 03 13 November 2018
Figure 6.c Relative Bioavailability Schema (Part 3)
6.2 Number of Subjects
Part 1: The est imated sample size of approximately 56 subjects is determined on the basis o f 
clinical rather than statist ical considerat ions. The number of subjects in this part of study  is 
consistent with phase 1 dose -finding studies. 
Part 2: With a sample size of 14 healthy subjects, the 90% CI for the AUC ratio is ex pected to be in 
the range of 84% to 119%, using an intrasubject AUC variabilit y of 27% in pat ients with cancer 
and assuming a TAK -788 AUC ratio of 1 in the fed versus fasted comparison. After accounting for 
2 potential dropouts in Part 2, the final sample size is up to 16 healthy subjects. Subjects who vomit  
within 8 hours after dosing will be considered nonevaluable for PK assessments. Subjects who are 
withdrawn fro m treatm ent before complet ing study -required PK assessments and subjects who are 
not non –PK-evaluable will not be replaced. 
Part 3 :With a sample size of 10 healt hy subjects, the 90% CI for the C maxratio is expected to be in 
the range of 87% to 115%, using an intrasubject C maxvariabilit y of 17% est imated in healt hy 
subjects. After accoun ting f or 2 potenti al dropouts in Part 3, the final sample size is up to 
12healt hy subjects. This sample size assumes no replacement of subjects who may drop out of the 
study  before the com pleting the PK sample co llections in Part 3. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 34of 92
Protocol Incorporating Amendment 03 13 November 2018
6.3 Duration of Study
6.3.1 Duration of an Individual Subject’s Study Participation
Subjects in the single rising dose part of the study  (Part 1) will be treated for 1 day  (single dose). 
Subjects in the food- effect part of the study  (Part 2) and the relat ive bioavailabilit y part of the 
study  (Part 3) will receive 2 single doses separated by  a ≥7-day washout. 
Subjects will be fo llowed for 30 days (window of up to 2 days after the Day 30 [Part 1] or Day 38 
[Parts 2 and 3] visits) after the last dose of TAK -788. For Part 3, safet y phone conferences will 
occur on Day  15 and 30 days after the last dose (window of up to 2 days after Day  38).
6.3.2 End of Study/Study Completion Definition and Planned Reporting
6.3.2.1 Definition of Trial Discontinuation
The tri al may be discont inued for nonsafet y reasons, such as:
A finding (eg, PK, pharmacodynamic, efficacy, biologic targets) from another nonclinical or 
clinical trial using the trial treatment(s) results in the trial being stopped for a non –
safet y-related reason.
Data from co mparator(s), drug(s) of the same class, or methodol ogy(ies) used in this trial 
beco me available and results in the trial being stopped for a non –safet y-related reason.
The tri al is stopped because of nonscientific and nonsafet y reasons, such as slow enrollment.
The tri al may be discont inued for safet y reasons:
Early trial terminat ion because of unant icipated concerns o f safety  to the trial  subjects arising 
from nonclinical studies or clinical trials wit h the tri al treatm ent(s), drug(s) of the same class, 
or methodol ogy(ies) used in this trial.
6.3.2.2 Criteria for Premature Termination or Suspension of Trial Sites
A trial site may  be terminated prem aturely  or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensur e 
adequate performance of the trial, or as otherwise permitted by  the contractual  agreement. 
6.3.2.3 Procedures for Premature Termination or Suspension of the Trial or the Participation of 
Trial Site
If the sponsor, an inst itutional review board (IRB), or regulat ory authori ty elects to terminate or 
suspend the trial or the participat ion of an invest igational si te, a tri al-specific procedure for early  
termination or suspensio n will be provided by the sponsor; the procedure will be fo llowed by  
applicable invest igational si tes during the course of terminat ion or tri al suspensi on.
6.3.3 Time Frames for Primary and Secondary Endpoints to Support Disclosures
Please refer to Table 6.afor disclosures information for all primary and secondary  endpoints. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 35of 92
Protocol Incorporating Amendment 03 13 November 2018
Table 6.a Primary and Secondary Endpoints for Disclosures
Endpoint Maximum Time Frame
Primary
Part 1: safety profile of orally administered TAK -788.
Number and percentage of subjects with 1 or more adverse events.
Number and percentage of subjects with 1 or more serious adverse events.
Number and percentage of subjects with clinically defined abnormal lab oratory 
values.
Number and percentage of subjects with clinically defined abnormal vital signs. Up to 30 days after last dose
Part 2: summary statistics of the PK parameters for TAK -788 under fasted 
conditio ns or following a low -fat meal.
Cmax.
tmax.
AUC t.
AUC ∞.
t1/2z.Up to 7 days following each 
dose
Part 3: summary statistics of the PK parameters for TAK -788 with different DiC 
under fasted conditions.
Cmax.
tmax.
AUC t.
AUC ∞(if data permitted).
t1/2z.Up to 7 days following each 
dose
Secondary
Part 1:summary statistics of the PK parameters for TAK -788 and its 2 active 
metabolites, AP32960 and AP32914 under fasted conditions.
Cmax.
tmax.
AUC t.
AUC ∞.
t1/2z.Up to 7 days
Part 2 : assess the safety profile of TAK -788 under fasted conditions or following a 
low-fat meal.Up to 30 days after last dose
Part 3 : assess the safety profile of TAK -788 under fasted. Up to 30 days after last dose
Footnotes are on last table page.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 36 of 92
Protocol Incorporating Amendment 03 13 November 2018
Table 6.a Primary and Secondary Endpoints for Disclosures (continued)
Endpoint Maximum Time Frame
Exploratory
AUC #, area under the concentration-time curve from time 0 to infinity, calculated using the observed value of the last 
quantifiable concentration; AUC t, area under the concentration-time curve from time 0 to time t; C max, maximum 
observed plasma concentration; PK, pharmacokinetic; t 1/2z, terminal disposition phase half-life; t max, time to first 
occurrence of C max. 
6.3.4 Total Study Duration
It is anticipated that this study will last for approximately 10 months.CCI
Property of Takeda: For non-commercial use se from timeom tim
the concehe conc
macokinetacokine
onn
s studytudy wymsrms of Use
e only and subject to the applicable Term
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 37of 92
Protocol Incorporating Amendment 03 13 November 2018
7.0 STUDY POPULATION
Healthy subjects who m eet all  of the inclusio n criteria and none of the exclusio n criteria will be 
enrolled in this study.
7.1 Inclusion Criteria
Each subject must meet all the fo llowing inclusio n criteria to be enrolled in the study . 
1.Aged 18 -55 years at the time of informed consent. 
2.Healthy subjects defined as the absence of acute or chronic clinically  significant devi ations 
from norm al in medical history , physical examinatio n, electrocardi ogram  (ECG), and clinical 
laboratory determinat ions at screening. 
3.Body  weight of ≥45 kg (women) or ≥55 kg (men) and a body mass index of 18.0 -30.0 kg/m2at 
screening. 
4.Norm al baseline PFTs ( ≥80% of predi cted norm al for sp irometry, lung vol umes, and DLco) 
Parts 1, 2, and 3; and chest CT scan at screening for Parts 1 and 2. 
5.Nonsmoker (never smoked or >20 y ears fro m last occurrence of smoking). 
6.Norm al organ funct ion including hepat ic, renal, and bone marrow funct ion. 
7.Agree to practi ce effective contraception (see Section 8.7for details). 
8.Voluntary  written consent must be given before performance of any study -relate d procedure 
not part of standard medical care, with the understanding that consent may be withdrawn by 
the subject at any  time without prejudice to future medical care.
9.The subject must be able to understand the requirements of the study and be willing to comply 
with the study  requi rements and provi de thei r wri tten informed consent to participate in the 
study . 
7.2 Exclusion Criteria
Subjects m eeting any o f the following exclusio n criteria are not to be enrolled in the study .
Medical History  and Concurrent Di seases
1.Ongo ing or prior pulmo nary disease including asthma, chronic obstructive pulmo nary disease, 
interstitial lung disease, and pneumo nitis including but not limited to drug -related 
pneumo nitis. 
2.Any history  of cardi ovascular di sease including a history  ofcongenital pro longed QT 
syndro me or unexplained cardiac arrest.
3.Manifestati ons of malabsorption due to prior GI surgery , GI di sease, or for an unknown other 
reason that may  alter the PK of TAK -788.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 38of 92
Protocol Incorporating Amendment 03 13 November 2018
4.Pulmo nary infect ion ongoing or within 30 days of informed consent.
5.Current or recent (within 3 months) GI disease.
6.Any major surgery  within 4 weeks before study  drug administration.
7.Blood transfusio n within 4 weeks before study  drug administration. 
8.History  of bleeding disorder.
9.Inabilit y to tolerate oral  medica tion. 
10.Inabilit y to undergo venipuncture and/or tolerate venous access. 
11.Inabilit y to tol erate m ultiple bl ood sam pling. 
12.Ongo ing or active infection, including but not limit ed to, the requirement for intravenous (IV) 
antibiotics. 
13.Positive sero logy or a kn own history  of hepati tis B virus (HBV), hepat itis C virus (HCV), or 
HIV. 
14.Pregnancy or breastfeeding (see Section 8.7for details). 
Physical and L aboratory  Test Findings
15.Any clinically  significant abnormalit y at screening of cardiac, hepat ic, renal, respiratory , GI, 
endocrine, immuno logic, dermatologic, hematologic, neuro logic, or psychiatric disease.
16.Resting blood pressure >140/90 mmHg at screening (a single repeat measurement is allowed if 
the init ial measurement is outside these limits).
17.Resting pulse rate <45 beats per minute.
Allergies and Adverse Drug Reactions
18.History  of severe allergy /hypersensi tivity reacti on or ongoing allergy/hypersensit ivity 
reacti on, as j udged by  the invest igator, or history  of hypersensit ivity to EGFR/HER2 
inhibitors.
Prohibited Treatments and Therapies 
19.Prior exposure to TAK -788.
20.Exposure to any  small  molecule drug treatm ent, incl uding invest igational small  molecule 
drugs, within 4 weeks or bi ologic drug treatm ent, including invest igational biologics, wi thin 
16weeks before study drug administration. 
21.Use of any  prescri ption or over -the-counter (OTC) stomach acid controllers wit hin 2 weeks 
before study  drug administrati on.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 39of 92
Protocol Incorporating Amendment 03 13 November 2018
22.Use of any  other drugs, including OTC medications, nutrit ional supplements, or herbal 
preparati ons (including St. John’s wort) within 1 week before study  drug administrati on 
(except occasional use of acetaminophen and ibuprofen, which are allowed up to 24 hours 
before dosi ng). 
23.Consumption o f any food or beverages containing grapefruit, Seville oranges, blood oranges, 
or pom egranates wi thin 1 week before study  drug administrati on.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 40of 92
Protocol Incorporating Amendment 03 13 November 2018
8.0 STUDY DRUG
8.1 Study Drug Administration
8.1.1 Dose Escalation Phase (Part 1)
TAK -788 will be supplied as 20 -mg and/or 40 -mg capsules (DiC), if the 40 -mg capsules are 
available at the time of the study . 
In each cohort of 8 subjects, 6 subjects will receive a single dose of TAK -788 and 2 subjects will 
receive a single dose of placeb o during the dose escalat ion phase (Part 1) under fast ing condit ions 
(see Section 8.1.2 ). TAK -788 dosing will begin at 20 mg (Cohort 1) and escalat e to 40 mg 
(Cohort 2), 80 mg (Cohort 3), 120 mg (Cohort 4), up to 160 mg (Cohort 5). 
All protocol -specific criteria for administering study  drug must be m et and docum ented before 
drug administration. Study  drug will be administered only  to eli gible subjec ts under the 
supervisio n of the invest igator or ident ified subinvestigator(s). The investigator(s) will remain 
blinded to the treatment in Part 1. 
Subjects in Part 1 will receive a single dose of TAK -788 on Day  1 following an overnight fast 
(nothing to ea t for at least 10 hours before and 4 hours after the TAK -788 dose). The drug product 
shoul d be administered with 240 mL (8 fluid ounces) of water. No food should be allowed for at 
least 4 hours postdose.
Water can be allowed as desired except for 1 hour be fore and after drug administration. Subjects 
shoul d receive standardized meals scheduled at the same time in each period of the study .
Before each dose escalat ion in Part 1, the investigator and sponsor will review the safet y dat a from 
the previous dose co hort and will consider new safety data fro m nonclinical sources and the 
ongoing study  in pat ients with NSCLC (AP32788 -15-101). 
8.1.2 Food Effects Study Phase (Part 2)
Before starting Part 2, the sponsor will evaluate the safet y and tol erabilit y of the dose iden tified in 
Part 1 and will include all available data, nonclinical and clinical, fro m both healt hy subjects and 
patients in the ongoing clinical trial. 
Subjects in Part 2 will receive a single dose of TAK -788 DiC form ulation identified in Part 1 on 
Day 1, with or wi thout a l ow-fat meal, foll owed by administration under the alternate treatment 
condi tion (f astedfed or fe dfasted) on Day  8 (at least 7 days apart). 
For fasted treatment: 
Following an overnight fast of at least 10 hours, subjects should be adm inistered the drug 
product with 240 mL (8 fluid ounces) of water. 
No food shoul d be allowed for at least 4 hours postdose. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 41of 92
Protocol Incorporating Amendment 03 13 November 2018
Water can be allowed as desired except for 1 hour before and after drug administration. 
Subjects should receive standardized meals scheduled at the same t ime in each period of the 
study .
For fed treatment:
Following an overnight fast of at least 10 hours, subjects should start the recommended low -fat 
meal 30 minutes before administration of the drug product. 
Study  subjects should eat this meal in 30 minutes or less; however, the drug product should be 
administered 30 minutes after the start of the meal. 
The drug product should be administered with 240 mL (8 fluid ounces) of water. No food 
shoul d be allo wed fo r at least 4 hours postdose. 
Water can be allowed as desired except for 1 hour before and after drug administration. 
Subjects should receive standardized meals scheduled at the same t ime in each period of the 
study .
The standard low -fat meal will be provi ded and served in the clinic by site personnel before dosing 
on Day  1 or Day  8 (or extended if the C trough/Cmaxratio is >5% at the same dose from Part 1). This 
meal will have the approximate composit ion described in Table 8.a. 
Table 8.a Low -fat Meal Content
Food Item Calories (kcal) (a) Fat (a) Carbohydrates (a) Protein (a)
2 Slices of white bread, 
toasted129 1.8 g 24.0 g 4.0 g
1 Teaspoon low -fat 
margarine24 2.8 g trace Trace
1 Tablespoon jam 56 0.3 g 13.8 g Trace
5 Ounces of apple juice 73 0.2 g 18.1 g 0.1 g
Total grams — 5.1 g 63.3 g 9.3 g
Total calories (kcal) 336 46 253 37
% Of total calories 100 14 75 11
(a) Source; US Department of Agriculture Nutrient Database for Standard Reference, Release 18 (August 2005). 
8.1.3 Relative Bioavailability (Part 3)
Subjects in Part 3 will receive a single dose of TAK -788 160 m g test Di C (Pro cess B) or a single 
dose of TAK -788 160 mg reference DiC (Process A) under fasted conditions on Day 1 or Day 8 
following an overnight fast of at least 10 hours. The drug product should be administered with 
240mL (8 fluid ounces) of water. No food should b e allowed f or at l east 4 hours postdose.
Water can be allowed as desired except for 1 hour before and after drug administration. Subjects 
shoul d receive standardized meals scheduled at the same time in each period of the study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 42of 92
Protocol Incorporating Amendment 03 13 November 2018
8.2 Definitions of DLT
DLTs will be summarized by category  (hematol ogic and nonhematologic) and by MedDRA 
preferred term. Toxicit y grade will be evaluated according to the National Cancer Inst itute 
Commo n Termino logy Criteria for Adverse Events (NCI CTCAE), versio n 5.0 [17]. These criteri a 
are provided in the study  manual . A DLT i s any  Grade ≥3 nonhematologic toxicit y, hematologic 
toxicity, or l aboratory  abnorm ality that occurred wit hin 5 days fo llowing the administration of 
study  drug and is considered by  the invest igator to be at least p ossibly related to therapy  with 
TAK -788. 
8.3 Dose Escalation Rules
For each cohort, the invest igator and sponsor will confirm the safet y and tol erabilit y of the 
administered dose on Day  5 before proceeding to the next planned higher dose. This assessment 
willbe based on all clinical findings such as AEs, vital signs, ECGs, PFTs, clinical laboratory  
tests, and physical examinat ion. Once adequate subject safet y and tol erabili ty are confirmed, 
enrollment in the next dose level will proceed. The fo llowing cri teria will be applied to subjects 
dosed with TAK -788 and m ust be met to proceed to next dose level:
No DLTs have occurred at the current dose level.
All Grade ≥2 treatm ent-related AEs reso
lve to Grade ≤1 or return to baseline by Day 5. If a 
Grade ≥2 treatment -related AE has not resolved to Grade ≤1 or returned to baseline by Day 5, 
the assessment will be repeated on Day  8 and Day  15, if necessary , to ensure all Grade ≤2 
treatm ent-related AEs have reso lved to Grade ≤1 or returned to baseline before escalat ion to 
the next dose . 
If any clinically significant serious adverse reaction or other findings are observed at any dose, 
the invest igator and sponsor may terminate dose escalat ion in this study . 
8.4 Criteria for Tolerable Dose
The dose is considered tolerable if ≤1 of 6 subjects experiences a study  drug –related DLT at the 
given dose within 5 days of dosing.
8.5 Excluded Concomitant Medications and Procedures
The fo llowing m edicat ions and procedures are prohibited during the study :
Other invest igational medicinal produ cts or devices.
Blood products or blood donation. 
Prescri ption medications, except as noted in Sect ion
 8.6.
Nutraceuticals, including St. John’s wort, ginseng, kava, ginkgo bilo ba, and melatonin.
Immunizati ons.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 43of 92
Protocol Incorporating Amendment 03 13 November 2018
Intake of known inhibitors/inducers of cytochrome P450 3A4 (excluding study  drugs) (see 
Appendix D).
OTC medicat ions, except as noted in Section 8.6.
Vitamin supplements. 
Proton pum p inhibitors (eg, omeprazo le, eso meprazole, and pa ntoprazol e). 
H2-receptor antagonists (eg, ranit idine, famotidine, cimet idine, and nizat idine). 
Medicat ions that are known to be associated with development of torsades de pointes. 
8.6 Permitted Concomitant Medications and Procedures
Occasio nal use of acetam inophen ≤1 g/day is permitted. Other OTC medicat ion must be approved 
by the sponsor on a case -by-case basis.
Treatment with neutralizing antacids is not permitted less than 4 hours before and wit hin 8 hours 
after receiving a dose of TAK -788.
Oral contracep tive pills and any  other ty pe of horm onal contracepti on is permitted.
Use of ant iemetics is permitted per standard institutional pract ice, if needed to control nausea and 
vomiting. 
Other concomitant medicat ions will be assessed on a case -
by-case basis.
All conco mitant m edicat ion use must be recorded on the appropriate eCRF. 
8.7 Precautions and Restrictions
It is not known what effects TAK -788 has on human pregnancy  or devel opment of the embry o or 
fetus. Women who are pregnant or breastfeeding will not be allowed to take part in this study . 
Women participating in this study  shoul d avoi d becoming pregnant or nursing a baby, and men 
subjects should avo id impregnating a female partner for 16 weeks (4 months) after the last dose of 
TAK -788. Nonsterilized women of reproducti ve age and male subjects should use effect ive 
methods of contraception through defined periods during and after study  treatm ent as specified 
below.
Women must meet 1 of the fo llowing cri teria:
Postmenopausal  for at l east 1 year before the scre ening visit, OR
Surgically sterile, OR
If they  are of  childbearing potential, agree to practice 2 effect ive methods of contraception 
from the time of signing of the informed consent form (ICF) through 16 weeks (4 months) 
after the l ast dose of study  drug, OR
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 44of 92
Protocol Incorporating Amendment 03 13 November 2018
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the subject. (Periodic abstinence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods] and withdrawal are not acceptable methods of contraceptio n.)
Agree to not donate eggs (ova) and male subjects must agree not to donate sperm during the 
course of this study  and f or 16 weeks (4 m onths) after receiving their last dose of study  drug. 
Men, even if surgically  sterilized (ie, status postvasectomy ) mu st agree to 1 of the fo llowing:
Agree to practice effective barrier contraception during the ent ire study  treatm ent peri od and 
through 16 weeks (4 months) after the last dose of study drug, OR
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the subject. (Periodic abstinence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods for the female partner] and withdrawal are not acceptable methods of contraception.)
Agree not to donate sperm during this s tudy and f or 120 day s after receiving their last dose of 
study  drug. 
Contraception methods meet ing the criteria defined above are provided in Table 8.b. If male 
condoms are used as a barrier method by  male subjects, thei r partners m ust use an intrauterine 
device (Copper T, or Progesteron T) or hormonal contraceptives (combined pills) instead of 
spermicide. 
Table 8.b Contraceptive Methods
Barrier Methods (Each Time the 
Subject Has Intercourse) Intrauterine Devices Hormonal Contraceptives
Male condom PLUS spermicide.
Cap (plus spermicidal cream or 
jelly) PLUS male condom and 
spermicide.
Diaphragm (plus spermicidal 
cream or jelly) PLUS male 
condom and spermicide.Copper T PLUS condom or 
spermicide.
Progesterone T PLUS condom 
or spermicide.Implants.
Hormone injections.
Combined pills.
Minipills.
Patches.
Vaginal ring PLUS male 
condom and s permicide.
8.8 Management of Selected EGFR TKI Class AEs
8.8.1 Pneumonitis
Invest igators must evaluate subjects who demonstrate potential signs/symptoms o f pneumo nitis, 
abnorm al DLco (decrease of >20% from baseline), and/or abnormal chest CT scan. If clinically 
indicated, high -dose corti costeroi d treatm ent should be init iated. Any DLco abnormalit ies and/or 
chest CT scan abnormalit ies will be fo llowed weekly  until resol ution.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 45of 92
Protocol Incorporating Amendment 03 13 November 2018
8.8.2 Nausea and Vomiting
Standard antiemet ics may be used for the treatment of nausea and vomi ting.
8.8.3 Diarrhea
Diarrhea m ay be treated at the invest igator’s discretion.
8.9 Blinding and Unblinding
Part 1 of this study  will be perf ormed in a double -blind m anner. 
Because TAK -788 and the placebo formulat ions may  be different in appearance, all subjects wil l 
be blindfo lded during dosing . An unblinded site pharmacist will dispense study  drugs. These 
personnel will not be invo lved in any other study  procedures (data collection, assessments, or 
docum entati on act ivities). 
One person in the bioanaly tical laborat ory will be unblinded to excl ude the PK samples collected 
from subjects who were dosed with placebo from the bioanalysis. 
If needed, 1 or 2 PK scient ists may also be unblinded to conduct the preliminary  PK data analysis 
during the study . 
After the subjec ts’ furlough begins on Day  3 of Part 1, the double -blind will beco me single -blind. 
The site staff, invest igator(s), and sponsor will be unblinded on Day 3 but study subjects will 
remain blinded unt il after the fo llow-up phone call 30 days after their last dose (window of up to 
2days after Day 30). After furlough on Day  3, the overall  randomizat ioncode will be broken for 
safet y evaluat ion and reporting purposes only. 
The study blind should not be broken before Day 3 of Part 1 except in a medical emergency where 
knowl edge of the treatment administered would affect the treatment of the emergency. The 
decisio n to break the blind will be made on a case-by- case basis, at the discretion o f the 
investigator in co llaboration with the sponsor/medical mo nitor. The a pplicable site standard 
operating procedure (SOP) will be fo llowed for blind -breaking procedures.
8.10 Description of Investigational Agents
TAK -788 drug product is a nonsterile oral DiC formulat ion. The active study  drug i s available as 
20 or 40 mg dosage strength capsules. The API has been synt hesized using 2 different processes 
(Process A and Process B). Before Amendment 1, all subjects in P art 1 of this study  received 
TAK -788 from Process B unmilled only with the capsule strength of 20 mg, and subjects in Part 2 
received TAK -788 f rom Process A wi th capsule strength of 20 mg. After Amendment 1, some 
additional cohorts in Part 1 m ay receive TA K-788 fro m Process A.
Process A and Process B are the same succinate salt in chemical structure but synthesized with 
different processes. The API fro m Process B has larger particle size and higher bulk densit y than 
that fro m Process A .
Placebo will  be comm ercially  available empt y size 2 capsul es. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 46of 92
Protocol Incorporating Amendment 03 13 November 2018
8.11 Preparation, Reconstitution, and Dispensation
TAK -788 study  drug will  be provi ded in appropri ately  labeled 30 -count, 60 -cc high -densi ty 
polyethylene bottles, with child -resistant caps and induct ion seals.
Study  drug bottles are considered to be bulk supplies, and are to be dispensed according to the site 
procedures, and according to instruction and guidelines provided in the study  pharmacy  manual .
TAK -788 i s an anticancer drug and caution should be exercised when h andling TAK -788 
capsules.
8.12 Packaging and Labeling
TAK -788 study  drug will  be provi ded by  Takeda and will be handled at the invest igative sites as 
blinded material in Part 1. TAK -788 study  drug i s packaged in accordance wit h all applicable 
regul ations. 
Theinvest igator will be notified of any expiry date or retest date extensio n of clinical study  
materi al during the study  conduct. On expiry date notification from the sponsor or designee, the 
site must com plete all instructions outlined in the notification, including segregat ion of expired 
clinical study  material for return to the sponsor or its designee. 
8.13 Storage, Handling, and Accountability
The recommended storage condit ion for TAK -788 is at a temperature thermostatically maintained 
at the usual customary  working environment of 15°C -30°C, as experienced in pharmacies, 
hospi tals, and warehouses (United States [US] Pharmacopeia 659 Packaging and Storage 
Requi rements).
The study  pharmacist or designee at the site will be responsible for handling and dispensing study 
drug and pl acebo, and for complet ing associated documentation. Supplies are shipped to the 
investigat ive site at appropriate intervals, depending on subject accrual. The site must use an 
appropriate dispensing log/accountabilit y form provided by  thesponsor, or an acceptable 
subst itute approved by the sponsor. An unblinded site pharmacist will dispense study drug to the 
subjects on the day  of administrati on. The si te SOP shoul d be fo llowed. 
All clinical trial material must be kept in an appropriate, limited -access, secure location unt il used 
or returned to the sponsor or designee. All study  medication must be stored under the condit ions 
specified on the label, and must remain in the original container unt il dispensed. A daily 
temperature l og of  the d rug storage area must be maintained.
The invest igator or designee must confirm that appropriate temperature condit ions have been 
maintained for all TAK -788 received and that any  discrepancies are reported and resolved before 
use of TAK -788.
The invest igato r is responsible for ensuring that deliveries of TAK- 788 and other study  materials 
from the sponsor are correctly  received, recorded, and handled, and stored safely  and properly in 
accordance with the Code of Federal Regulat ions (CFR) or national and local regulati ons.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 47of 92
Protocol Incorporating Amendment 03 13 November 2018
The investigator or designee must ensure that the study  medicati on is used in accordance with the 
approved protocol and is dispensed only to subjects enrolled in the study. To document appropriate 
use of study medication (TAK -788), the invest igator must maintain records of all study medicat ion 
delivery  to the si te, si te inventory , use by each subject, and return to the sponsor or designee.
8.13.1 Disposition of Used Supplies
All used bottles of study  drug m ust be destroy ed in an appropri ate m anner ac cording to the 
standard practice at each study  center. Destruction of such supplies will be documented, and a 
representative of the sponsor will verify disposit ion records.
No other use of TAK -788 intended for use in this study is authorized by the sponsor . The principal 
investigator or designee will be responsible for the appropriate handling and disposit ion of residua l 
study  drug. 
8.13.2 Inventory of Unused Supplies
At the complet ion of the trial, a final study  drug accountabilit y review will  be conducted. Any 
discrepancies must be investigated and all unused study  drug m ust be destroy ed on si te per the 
SOP of the invest igative site.
8.14 Other Protocol -Specified Materials
Not applicable 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 48of 92
Protocol Incorporating Amendment 03 13 November 2018
9.0 STUDY CONDUCT
This tri al will be conducted in com pliance wi th the protocol , GCP, applicable regulatory  
requi rements, and ICH guidelines.
9.1 Study Personnel and Organizations
The contact informat ion for the sponsor clinician for this study , the central  laboratory  and any 
additional clinical  laboratories, the coordinat ing investigator, and any other vendor may be found 
in the study  manual .
9.2 Arrangements for Recruitment of Subjects
Recrui tment and enro llment strategies for this study may include recruit ment from the 
investigator’s local practice or referrals from other physicians. If advert isements become part of 
the recruitment strategy , they  will be reviewed by  the IRB/independent ethics committee (IEC). It 
is not envisio ned that prisoners (or other populations that might be subject to coercion or 
explo itation) will be enro lled into this study .
9.3 Treatment Group Assignments
Subjects in Part 1 will receive a single dose of TAK -788 or pl acebo under fasted conditions. 
In Part 2, subjects will receive TAK -788 under fed or fasted conditions then crossover to receive 
TAK -788 under the altern ate condi tion (f ed versus fasted) after a washout of at least 7 days 
between doses of TAK -788.
In Part 3, subjects will receive TAK -788 Process B DiC (test) or Process A DiC (reference), then 
crossover to receive the alternate TAK- 788 (test or reference) f ormulation after a washout of at 
least 7 day s between doses of TAK -788.
Before dosing on Day 1, subjects will be assigned a rando mizat ion number in accordance with the 
rando mizat ion code generated by  the sponsor, the sponsor’s designee, or the clinical sit e. The 
rando mizat ion code will be maintained in a room with access restricted to pharmacy personnel 
only. 
Once a rando mizat ion number has been allocated to one subject, it may not be assigned to another 
subject. Subjects withdrawn prematurely fro m the stu dy will not be replaced.
9.4 Study Procedures
Refer to the schedule o f events ( Appendix A) for the timing of assessments. Subjects will be 
admitted to the c linical site on the day  before dosing day s. Study  drug administration will be 
considered time zero (starting of Day  1). Addi tional details are provi ded as necessary  in the 
sections that fo llow.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 49of 92
Protocol Incorporating Amendment 03 13 November 2018
9.4.1 Informed Consent
Each subject must provide written informed co nsent before any study -requi red procedures are 
conducted.
9.4.2 Subject Demographics
The date of birth, race, ethnicit y, and sex of the subject are to be recorded during screening.
9.4.3 Medical History
During the screening period, a complete medical history  will be c ompiled for each subject. 
9.4.4 Physical Examination
A physical examinat ion will be completed per standard of care at the times specified in the 
schedule of events ( Appendix A). A complete physical examinat ion must be performed at 
screening, the extent of which should be consistent with medical history .Subsequent physical 
examinat ions as described in the schedule of events may be directed to rel evant findings.
9.4.5 Subject Height
Height will be measured during screening only (within 21 days before the first dose of TAK -788).
9.4.6 Vital Signs
Vital sign m easurements including measurements of diastolic and systolic blood pressure, pulse 
rate, and oral temperature will be o btained at the times specified in the Schedules of Events 
(Appendix A). Subjects should sit quiet ly for at least 5 minutes before blood pressure is meas ured. 
When the timing of vital sign measurements coincides with the collect ion of blood samples, the 
vital sign measurements should be co mpleted first. When vital sign measurements are scheduled at 
the sam e time as an ECG and a blood draw, the vital sign m easurements will be obtained 
immediately  before the ECG and the blood draw, and the blood draw will be co llected at the 
scheduled time. If vital sign measurement results are abnormal, a repeat measure may be taken 
within 30 minutes. 
9.4.7 Pulmonary Function Tes ts
PFTs include spirom etry, lung vo lumes, and DLco. In Part 1, PFTs will be performed at s creening 
but no more than 7 days before Day 1, and at Day 3 before furlough. In Part s 2and 3 , PFTs will be 
perform ed at screening and at Day  3, Day  10, and/or Early  Terminat ion visit if indicated on the 
basis of pulmo nary symptom s. 
9.4.8 Drug, Alcohol, and Tobacco Testing
Urine drug testing and breath alcohol testing will be performed during screening using the site’s 
standard test panel. In addit ion to negative test resul ts during screening, subjects also must have 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 50of 92
Protocol Incorporating Amendment 03 13 November 2018
negat ive urine and alcoho l test results fo llowing confinement on Day  -1 before the first dose of 
TAK -788.
To test for use of nicotine products, a urine cotinine test will be performed during screening. In 
addition to a negative test result during screening, subjects also must have a negat ive ur ine cotinine 
test result fo llowing confinement on Day  -1 before the first dose of TAK -788.
In Part s 2and 3 of the study, subjects must also have negat ive ur ine drug, breat h alcohol, and urine 
cotinine test results the day  before the second dose of TAK -788 on Day  8. 
9.4.9 Pregnancy Test
In Part 1 of the study , a serum  -human chorionic gonadotropin ( -hCG) pregnancy test will be 
perform ed for wom en of childbearing potential during screening. In addit ion to a negat ive serum 
hCG pregnancy test at screening, female subjects also must have a negat ive serum hCG pregnanc y 
test following confinement on Day  -1 before the first dose of TAK -788 on Day  1.
In Part s 2and 3 of the study , female subjects must have a negative serum hCG pregnancy test at 
screening, Day  -1 (before first dose), and Day  7 (before the second dose of TAK -788 on Day  8). 
9.4.10 Concomitant Medications and Procedures
Medicat ions used by the subject and therapeuti c procedur es completed by the subject will recorded 
in the electronic case report form (eCRF) from signing of the ICF through 30 days after the last 
dose. See Section 8.5and Section 8.6for a list of medicat ions and therapies that are prohibited and 
allowed, respect ively, during the study. 
9.4.11 AEs
AEs, serious and nonserious, will be recorded from the signing of ICF through 30 days after the 
last dose of study  drug, wi th a follow-up phone call on Day 30 (window of up to 2 days after 
Day 30) f or Part 1 subjects or on Day 38 (window of up to 2 days after Day 38) for subjects in 
Parts 2and 3 . Refer to Section 10.1 for details regarding definit ions, documentation, and reporting 
of pretreatm ent events (PTEs), AEs, and SAEs. 
9.4.12 Enrollment
A subject i s considered to be enrolled in the study  when the subject has met all eligibilit y criteria 
and is randomized to a study group (TAK -788 versus placebo in Part 1; fed versus fasted in Part 2; 
test versus reference formulation in Part 3 ). Procedures for complet ing the enrollment informat ion 
are described in the study  manual . 
9.4.13 ECG
Triplicate 12- lead ECG will be administered at the time points specified in the Schedules of Events 
(Appendix A). ECG measurements m ust be taken at screening; on Days - 1, 1, and 3 in Parts 1, 2, 
and 3; and on Days 7, 8, and 10 in Part s 2and 3. On Days 1 and 8, ECG measurements will be 
obtained between 4 and 6 hours postdose. The clinical site’s ECG machine may be used to obtain 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 51of 92
Protocol Incorporating Amendment 03 13 November 2018
the ECG. When the timing of an ECG coincides wit h the collect ion of blood samples, the ECG 
shoul d be com pleted first. When an ECG is scheduled at the same t ime as vital signs and a blood 
draw, the ECG will be obtained after the vital signs and before the blood draw, and the blood draw 
will be co llected at the scheduled time.
9.4.14 Chest CT Scan
A chest CT scan will be performed at screening (wit hin 28 days before dosing) for Parts 1 and 2; 
this scan can be a low -dose scan. The fo llow-up chest CT s can, if needed on the basis o f 
symptoms, should be a high -resolution chest CT scan with the appropriate dose of radiat ion. No IV 
contrast agent should be used. 
9.4.15 Clinical Laboratory Evaluations
Clinical laboratory  evaluat ions will be performed locally. Addi tional laboratory  samples may be 
taken at the discretion o f the invest igator (eg, if the results of any tests fall outside reference ranges 
or if clinical symptoms necessitate testing). Handling and shipment of clinical laboratory samples 
will be outlined in the study manual. Clinical laboratory evaluat ions will be performed as outlined 
below: 
9.4.15.1 Clinical Chemistry, Hematology, and Urinalysis
Blood sam ples f or analysis of the clinical chemistry  and hematol ogy parameters shown in 
Table 9.aand urine samples for analysis o f the param eters shown in  Table 9.bwill be obtained as 
specified in the schedule of events. 
Table 9.a Clinical Chemistry and Hematology Tests
Hematology Serum Chemistry (a)
Hemoglobin
CBC with 5 -part differential
Platelet count
RBC count
Reticulocyte countAlbumin
Alkaline phosphatase
Alanine aminotransferase
Amylase
Aspartate aminotransferase
Bilirubin, direct
Bilirubin, total
Blood urea nitrogen
Calcium
Carbon dioxide
Chloride
CreatinineCreatine phosphokinase
γ-Glutamyl transferase
Glucose
Lactate dehydrogenase
Lipase
Magnesium
Phosphate, inorganic
Potassium
Protein, total
Sodium
Urate
CBC, complete blood count; RBC, red blood cell. 
(a) For screening serum chemistry, subjects must be fasting (nothing except water) for 8 hours before the 
measurement. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 52of 92
Protocol Incorporating Amendment 03 13 November 2018
Fasting serum glucose will be measured at screening only . Subjects are required to fast overnight 
(nothing except water and/or protocol allowed medicat ions [see Section 8.6]after midnight or for a 
minimum o f 8 hours) for each of these measurements. 
In addit ion to fast serum glucose , serum  glucose will also be measured at the time po ints specified 
in the Schedules of Events ( Appendix A). Subjects are not requi red to fast for these measurements.
The Cockcroft -Gault formula will be used to estimate creatinine clearance as fo llows: 
          	           	          	
=	[(140−   )•    (  )	]	/	[72•     	           (  /  ) ]	
For female subjects, the result of the formula above should be mult iplied by 0.85. 
Table 9.b Clinical Urinalysis Tests
Bilirubin
Glucose
Ketones
Leukocytes
NitriteOccult blood 
pH
Protein
Specific gravity
Urobilinogen
9.4.15.2 Serology
Serol ogy tests performed at screening will include ant i-HIV ant ibodies, HBV surface ant igen, and 
anti-HCV ant ibody . 
9.4.15.3 Coagulation
Prothrombin internat ional norm alized rati o will  be measured only  if alanine aminotransferase or 
aspartate aminotransferase is >3 times the upper limit of normal (ULN). 
9.4.16 PK Measurements
Blood samples for PK analysis o f TAK-788 will be collected over a 7 -dayperiod (0 -168 hours) for 
Parts 1 and 2 and over a 3 -day period (0 -72hours) for Part 3 following the dose of TAK -788. Time 
points are specified in the PK blood sampling schedules ( Appendix A). While the primary purpose 
of collect ing PK samples is for measuring plasma concentrations of TAK -788 and its act ive 
metabo lites, AP32960 and AP32914, if deemed necessary and pending technical feasibilit y, the 
sampl es co llected may also be used for future performance of exploratory measurements of 
TAK -788 metabo lite levels to further understand TAK -788 m etabo lism in humans. The dates and 
exact times of administration of TAK-788 before collect ion of the blood sample f or PK analysis 
and the dates and exact times of the postdose PK sample collection will be recorded on the eCRF. 
Urine samples for PK analysis of the renal clearance of TAK- 788 will be obtained at the time 
points specified in the PK plasma and urine sampling schedules ( Appendix A). While the primar y 
purpose of collect ing urine PK samples is for measuring urine concentrations of TAK -788, if 
deem ed necessary and pending technical feasibilit y, the urine samples collected may also be used 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 53of 92
Protocol Incorporating Amendment 03 13 November 2018
for future perform ance of exploratory  measurem ents of TAK -788 m etabo lite levels to further 
understand TAK -788 metabolism in humans. The date and exact time of the predose void s; the 
dates and exact times o f administration of TAK -788 before the start of urine sample co llection for 
PK analysis; and the total vo lume o f each vo ided sample fo llowing administration of TAK -788 
will be recorded on the eCRF. 
For subjects in Parts 2 and 3, the morning dose on Day  8 shoul d occur at approximately  the same 
time as the morning dosing t ime on Day 1. When the timing of a PK or safety laboratory blood 
sample coincides with the timing of ECG measurements, the ECG will be completed before the 
blood sam ple collect ion. 
9.5 Completion of Study Treatment for Individual Subjects
Subjects will be enro lled into Part 1, Part 2, or Part 3 of the study and will be considered to have 
completed study  treatment after they have received the prescribed study drug t reatments in Part 1, 
Part 2, or Part 3 of this study  (single dose for Part 1 and two separated doses for Parts 2 and 3).
9.6 Discontinuation of Treatment With Study Drug and Subject Replacement
Any subject who vo luntarily wit hdraws consent or is discontinued ( eg, because o f an AE) from the 
study  before com pletion will be considered withdrawn fro m the study . Treatm ent wi th study  drug 
may also be discont inued for any of the fo llowing reasons:
Occurrence of into lerable AE, as assessed by the investigator or design ee. 
Clinically significant ly abnormal vital signs, ECG, clinical laboratory, or physical examinat ion 
assessments, as assessed by  the invest igator. 
Pregnancy.
Withdrawal o f consent. 
Lost to follow -up.
Administrative reasons (eg, sponsor decisio n). 
Majorprotocol vio lation. 
If, in the opinio n of the invest igator, it is in the best interest of the subject.
Non-compliance wi th study  requi rements and restrict ions.
Use of a concomitant medicat ion that, in the opinion of the invest igator, could interfere with
the study  procedures or data integrity  or com promise the safet y of the subject.
Positive ur ine drug screen, CO breath test, or breath alcoho l test at admission to any study visit.
Emesis wit hin 8 hours of drug ingest ion (to be evaluated by  the invest igato r or designee on a 
case-by-case basis).
Terminat ion of the study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 54of 92
Protocol Incorporating Amendment 03 13 November 2018
When an event such as a family  emergency , a transient intercurrent illness (such as a cold) 
unrelated to study  drug, or a rem ediable act of non -compliance prevents a subject from 
participat ing in a scheduled visit but the subject wishes to continue in the study , with the 
agreem ent of the invest igator, the research site staff may attempt to reschedule the visit and retain 
the subject in the study . 
If a subject is prematurely discont inued fro mpartici pation in the study  for any  reason after drug 
administration, the invest igator or designee must make every effort to perform the assessments 
scheduled for the fo llow-up visit. The reason for wit hdrawal will be recorded in the eCRF and the 
subject’s source m edical  record.
Subjects in Parts 2 and 3 who discontinue their participat ion in the study  before receiving the 
Day 8 dose will undergo the safet y follow-up as specified in the Schedules of Events. 
Replacement of subjects is not planned but may oc cur under special circumstances at the sponsor’s 
discreti on, in agreement with the investigator.
9.7 Study Compliance
Study  drug will be administered or dispensed only  to eligible subjects by  an unblinded site 
pharmacist and will be under the supervisio n of the invest igator or ident ified subinvest igator(s). 
The pharmacist will be unblinded in Part 1. The appropriate study personnel  will maint ain records 
of study  drug recei pt and dispensing. Subject compliance wit h study  drug administration will be 
confirmed according to standard procedures at the clinical site. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 55of 92
Protocol Incorporating Amendment 03 13 November 2018
10.0 ADVERSE EVENTS
10.1 Definitions
10.1.1 PTE
A PTE i s any  untoward m edical occurrence in a subject who has signed informed consent to 
participate in a study  but before administration of any study  medicat ion; it does not necessarily  
have to have a causal relat ionship wit h study  parti cipat ion.
10.1.2 AE Definition
AE means any untoward me dical  occurrence in a subject or subject administered a pharmaceut ical 
product; the untoward medical occurrence does not necessarily have a causal relat ionship wit h this 
treatm ent. An AE can therefore be any unfavorable and unintended sign (including a cli nically  
significant abnorm al laboratory  finding), symptom, or disease temporally  associ ated wi th the use 
of a medicinal (investigational) product whether or not it is related to the medicinal product. This 
includes any newly occurring event, or a previous condi tion that has increased in severit y or 
frequency  since the administrati on of  study  drug.
An abnormal laboratory value will not be assessed as an AE unless that value is considered by the 
investigator to be a clinically significant change from baseline .
10.1.3 SAE Definition
An SAE is any  untoward m edical  occurrence that, at any  dose:
Results in death.
Is life-threatening (refers to an AE in which the subject was at risk of death at the time of the 
event. It does not refer to an event that hypothetically might have caused death if it were more 
severe).
Requi res in -patienthospitalization or prolongation of an existing hospitalization (see 
clarificati onin the paragraph in Sect ion 10.2 on planned hospitalizat ions).
Results in persistent or significant disability or incapacity . (Disabilit y is defined as a 
substant ial disrupt ion of a person’s abilit y to conduct normal lif e functi ons).
Is a congenital anomaly/birth defect .
Is a medically important event . This refers to an AE that may  not resul t in death, be 
immediately  life threatening, or require hospitalization, but may be considered serious when, 
on the basis of appropri ate m edical j udgment, m ay jeopardi ze the subject, require medical or 
surgi cal interventi on to prevent one of the outcomes listed above, or involves suspected 
transmissio n via a medicinal product of an infect ious agent. Examples of such medical events 
inclu de allergic bronchospasm requiring intensive treatment in an emergency depart ment or at 
home, blood dyscrasias or convulsio ns that do not result in in -patient hospi talizati on, or the 
development of drug dependency  or drug abuse; any  organism , virus, or inf ectious parti cle 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 56 of 92
Protocol Incorporating Amendment 03 13 November 2018
(eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.
In this study, intensity for each AE, including any lab abnormality, will be determined using the 
NCI CTCAE, version 5.0, effective date 27 November 2017 [17]. Clarification should be made 
between an SAE and an AE that is considered severe in intensity (Grade 3 or 4), because the terms 
serious and severe are notsynonymous. The general term severe is often used to describe the 
intensity (severity) of a specific event; the event itself, however, may be of relatively minor 
medical significance (such as a Grade 3 headache). This is notthe same as serious , which is based 
on subject/event outcome or action criteria described above, and is usually associated with events 
that pose a threat to a subject’s life or ability to function. A severe AE (Grade 3 or 4) does not 
necessarily need to be considered serious. For example, a white blood cell count of 1000/mm3to 
less than 2000/mm3is considered Grade 3 (severe) but may not be considered serious. Seriousness 
(not intensity) serves as a guide for de fining regulatory reporting obligations.
10.2 Procedures for Recording and Reporting AEs and SAEs
All AEs spontaneously reported by the subject a nd/or in response to an open question from study 
personnel or revealed by observation, physical examination, or other diagnostic procedures will be 
recorded on the appropriate page  of the eCRF (see Section  10.3 for the period of observation). Any 
clinically relevant deterioration in laboratory assessments or other clinical finding is considered an 
AE. When possible, signs and symptoms indicating a common underlying pathology should be 
noted as 1 comprehensive event.
Regardless of causality, SAEs and serious PTEs (as defined in Section  10.1)  must be reported (see 
Section 10.3 for the period of observation) by the investigator to the Takeda Global 
Pharmacovigilance department or designee (contact information provided below). This should be 
done by faxing the SAE form within 24 hours after becoming aware of the event. The SAE Form, 
created specifically by Takeda, will be provided to each clinical study site. A sample of the SAE 
Form may be found in the study manual. Follow-up information on the SAE or serious 
pretreatment event may be requested by Takeda. SAE report information must be consistent with 
the data provided on the eCRF.
SAE Reporting Contact Information
Planned hospital admissions or surgical procedures for an illness or disease that existed before study drug was given are not to be considered AEs unless the condition deteriorated in an 
unexpected manner during the trial (eg, surgery was performed earlier or later than planned). For 
both serious and nonserious AEs, the investigator must determine both the severity (toxicity grade) 
of the event and the relationship of the event to study drug administration. For serious PTEs, the CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Usehe 
ade ade 
the termhe term
ribe the ribe th
ely yminomin
us, which, whi
ssociatedociat
ade 3 orde 3 or
cell counell cou
onsiderednsidere
obligatbligat io
d SAEsSAEs
n responsrespon
natatioion, on
Sectionection
sessmenessme
dicating aating
rious PTEous PT
rvativation)on
or desigdesi
m within within
keda, wieda, w
he studye stu
mayay be re beyy
on the en the
Fo
ofPl
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 57of 92
Protocol Incorporating Amendment 03 13 November 2018
investigator must determine both the severit y (toxici ty grade) of the event and the causalit y of the 
event in relat ion to study  procedures.
Sever ity (toxicit y grade) for each AE, including any lab abnormalit y, will be determined using the 
NCI CTCAE, versio n 5.0, effect ive date 27 November 2017 [17].The criteria are provided in the 
study  manual. Selected asymptomat ic laboratory values may also constitute AEs as defined by t he 
NCI CTCAE.
10.3 Monitoring of AEs and Period of Observation
AEs, both nonserious and serious, will be mo nitored throughout the study  as fo llows: 
AEs will be reported from the signing of informed consent through 30 day s after 
administration of the last dose of study  drug and recorded i n the eCRFs. 
SAEs will be monitored throughout the study  as foll ows:
–Serious PTEs will be reported to the Takeda Global Pharmacovigilance department or 
designee fro m the time of the signing of the ICF up to first dose of study drug, and will also  
be recorded in the eCRF. 
–Related and unrelated treatment -emergent SAEs will be reported to the Takeda Global 
Pharmacovigilance department or designee fro m the first dose of study  drug through 
30days after administration o f the last do se of study drug and recorded in the eCRF. After 
this peri od, only related SAEs m ust be reported to the Takeda Global Pharmacovigilance 
departm ent or desi gnee. SAEs shoul d be m onitored until they  are resolved or are clearly 
determined to be due to a subjec t’s stable or chronic condit ion or intercurrent illness(es).
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events
If a woman beco mes pregnant or suspects that she is pregnant while participat ing in this study, she 
must inform the invest igator immediately and permanent ly discont inue study  drug. The sponsor 
must al so be contacted immediately by  faxing a completed pregnancy  form to the Takeda Global 
Pharmacovigilance department or designee (see Section
 10.2). The pregnancy must be followed 
for the final pregnancy  outcom e.
If a female partner of a male subject beco mes pregnant during the male subject’s participat ion in 
this study , the s ponsor must also be contacted immediately by faxing a completed pregnancy for m 
to the Takeda Global Pharmacovigilance depart ment or designee (see Sect ion 10.2). Every  effort 
shoul d be made to follow the pregnancy for the final pregnancy  outcom e.
10.5 Procedures for Reporting Product Complaints or Medication Errors (Including 
Overdose)
A product complaint is a verbal, written, or electronic expression that implies dissat isfaction 
regarding the identit y, strength, puri ty, quali ty, or s tabilit y of a drug product. Individuals who 
ident ify a potential product complaint situat ion shoul d immediately report this via the phone 
numbers or e -mail addresses provided be low.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 58 of 92
Protocol Incorporating Amendment 03 13 November 2018
A medication error is a preventable event that involves an identifiable subject and that leads to 
inappropriate medication use, which may result in subject harm. While overdoses and underdoses 
constitute medication errors, doses missed inadvertently by a subject do not. Individuals who 
identify a potential medication error (including overdose) situation should immediately report this 
via the phone numbers or e-mail addresses provided below. 
Call center Phone number E-mail Fax
Product complaints in and of themselves are not AEs. If a product complaint results in an SAE, an SAE form should be completed a nd sent to  (refer to Section  10.2) . 
10.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, investigators, and IRBs or 
IECs, as applicable, in accordance with national regulations in the countries where the study is 
conducted. Relative to the first awareness of the event by/or further provision to the sponsor or 
sponsor’s designee, SUSARs will be submitted to the regulatory authorities as an expedited report 
within 7 days for fatal and life-threatening events and 15 days for other serious events, unless 
otherwise required by national regulations. The sponsor will also prepare an expedited report for 
other safety issues where these might materially alter the current benefit-risk assessment of an 
investigational medicinal product or that would be sufficient to consider changes in the 
investigational medicinal product’s administration or in the overall conduct of the trial. The 
investigational site also will forward a copy of all expedited reports to its IRB or IEC in 
accordance with national regulations. CCI
CCI
Property of Takeda: For non-commercial use only and subject to the aea
mplaint mplain
ectiontion101
and Regnd Re
ted unexed une
oryyauthoautyy
egulatulatioio
e event bevent
ted to theto t
g events even
oons. Thens. Th
ht materit mate
t or that or tha
duct’s aduct’s a
l forwarforwa
l regulatregulble Terms of Uset this this 
eb
applicab
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 59of 92
Protocol Incorporating Amendment 03 13 November 2018
11.0 STUDY COMMITTEES
Not applicable. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 60of 92
Protocol Incorporating Amendment 03 13 November 2018
12.0 DATA HANDLING AND RE CORDKEEPING 
The full details o f procedures for data handling will be documented in the data management plan. 
If selected for coding, AEs, PTEs, medical history, and concurrent condit ions will be coded using 
MedDRA. Drugs will be coded using the World Health Organizat ion (WHO) Drug Dict ionary.
12.1 eCRFs 
Com pleted eCRFs are required for each subject who signs an ICF.
The sponsor or its desig nee will supply invest igative sites with access to eCRFs and will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit  
the informat ion collected in the performance of this study  to the sponsor, contract research 
organi zation (CRO) partners, and regulatory  authori ties. Invest igative sites must complete eCRFs 
in English.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site.
Any change of, modificat ion of, or addit ion to the data on the eCRFs should be made by the 
investigator or appropriate site personnel . Correcti ons to eCRFs are recorded in an audit trail that 
captures the old informat ion, the new information, ident ificat ion of the person making the 
correcti on, the date the correction was made, and the reason for change.
The invest igator must review the eCRFs for completeness and accuracy and must sign and date the 
appropriate eCRFs as indicated. Furthermore, the investigator must retain full responsibilit y for 
the accuracy  and authenticit y of all data entered on the eCRFs .
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
arethe sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific docum ents, the i dentificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated ICFs, subject authorization forms regarding the use of 
personal healt h inform ation (if separate from the ICFs), electronic copy  of eCRFs, including the 
audit trails, and detailed records of drug disposit ion to enable evaluat ions or audits fro m regulatory 
authori ties, the sponsor, or its designees. Any source documentation printed o n degradable 
thermal-sensit ive paper should be photocopied by the site and filed with the original in the 
subject’s chart to ensure long term legibilit y. Furtherm ore, ICH E6 Section 4.9.5 requires the 
investigator to retain essent ial docum ents specified in ICH E6 (Secti on8) unt il at least 2 years 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 61of 92
Protocol Incorporating Amendment 03 13 November 2018
after the last approval of a market ing applicat ion for a specified drug indicat ion being investigated 
or, if an applicat ion is not approved, until at least 2 years after the invest igation is discont inued and 
regul atory  authori ties are notified. In addit ion, ICH E6 Section 4.9.5 states that the study  records 
shoul d be retained unt il an amount of time specified by applicable regulatory requirements or for a 
time specified in the clinical study  site agreement between the invest igator and sponsor.
Refer to the clinical study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval fro m the sponsor before disposing of any 
such documents.
Refer to the clinical study site agreement for the sponsor’s requirements on record retention. The 
investigator and the head of the institution should contact and receive written approval fro m the 
sponsor before disposing of any  such documents.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 62of 92
Protocol Incorporating Amendment 03 13 November 2018
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan will be prepared and finalized before database lock. This document will 
provi de further details regarding the definit ion of analysis variables and analysis methodology  to 
address all study  object ives. 
13.1.1 Analysis Sets
The study  analysis populations will consist of the following:
Randomized populat ion:All subjects who are randomized to receive study treatment in Part 1, 
Part 2, or Part 3.
Safety popul ation:All enro lled subjects who receive any study tr eatment in the treatment 
period.
PK populat ion:All subjects in the safet y popul ation who have no major protocol deviat ions 
that woul d affect the PK analysis and who have sufficient data to calculate PK parameters. 
This populat ion will be used for the PK a nalyses. Data from subjects who experience emesis 
within the first 8 hours following dosing may  be excluded from  the final  analysis (to be 
evaluated on a case -by-case basis).
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Dem ographic and basel ine characterist ics will be summarized descript ively. Mean, SD, minimum, 
median, and maximum will be calculated for continuous variables. Frequency and percentages 
will be calculated for categorical variables.
13.1.3 PK Analysis
Descript ive statistics, including arithmet ic mean, geometric mean, SD, coefficient of variat ion 
(%CV), minimum, median, and maximum, will be calculated and presented by dose level in Part 1, 
for each treatm ent under fasted versus fed condit ions in Part 2, and for each treatment (test vs 
reference drug formulat ion) under fasted condit ions in Part 3 for plasma concentrations of 
TAK -788 and its 2 active metabo lites, AP32960 and AP32914. 
Analysis of PK parameters will be performed for TAK- 788, AP32960, and AP32914. The 
concentration -time profi les will be analyzed using nonco mpart mental methods to estimate PK 
param eters in pl asma. The number of observat ions, ari thmetic m ean, geometri c mean, SD, %CV, 
median, minimum, and maximum values will be calculated for the PK parameters C max, tmax, 
AUC t, AU C∞, t1/2z, AUC extrap% (area under the curve fro m the last quantifiable concentration to 
infinit y calculated using the observed value o f the last quantifiable concentration, expressed as a 
percentage of AUC ∞), CL/F (apparent clearance after extravascular ad ministration, calculated 
using the observed value of the last quant ifiable concentration), V z/F (apparent vo lume of 
distribut ion during the terminal disposit ion phase after extravascular administration, calculated 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 63 of 92
Protocol Incorporating Amendment 03 13 November 2018
using the observed value of the last quantifiable concentration),  
In Part 2, PK parameters (natural log-transformed [ln]) of TAK-788, AP32960, and AP32914 will 
be compared under fasted versus fed conditions using an analysis of variance (ANOVA) model. 
The ANOVA model will include fasted versus fed condition, period, and sequence as fixed effects 
and subject nested within sequence as a random effect. Each ANOVA will calculate the 
least-squares mean (LSM), the difference between treatment LSMs, and the standard error 
associated with the difference. Residual, subject nested within sequence, and intersubject variance, 
along with the intrasubject and intersubject CV, will be reported. Ratios of LSM will be calculated 
using the exponential function of the difference between treatment LSMs from the analyses on the 
ln-transformed C max, AUC t, and AUC ∞. 
In Part 3, PK parameters (ln-transformed) of TAK- 788 for the test formulation (Process B DiC) 
and the reference formulation (Process A DiC) will be compared using an ANOVA model. The 
ANOVA model will include treatment (test versus reference), period, and sequence as fixed 
effects and subject nested within sequence as a random effect. Each ANOVA will calculate the 
LSM, the difference between treatment L SMs, and the SE associated with the difference. Residual, 
subject nested within sequence, and intersubject variance, along with the intrasubject and 
intersubject CV, will be reported. Ratios of LSM will be calculated using the exponential function 
of the difference between treatment LSMs from the analyses on the ln-transformed C max, AUC t, 
and AUC ∞ (if data permitted).
13.1.4 Safety Analysis
Safety and tolerability parameters will be listed by subject, study group, and treatment group, and 
displayed in summary tables using descriptive statistics. All subjects receiving placebo in Part 1 
will be pooled and analyzed as one placebo group. Original terms used in the eCRFs by the 
investigator or designees to identify AEs will be coded using MedDRA (version 20.0 or higher) 
terminology.
The number and percentage of subjects with TEAEs will be summarized by MedDRA System 
Organ Class and Preferred Term and study group and by study group by maximum severity and 
relationship to study treatment. A TEAE is any AE that is new in onset or was aggravated in 
severity or frequency following the first dose of study drug, up to and including the last visit of the 
study.
Descriptive statistics will be calculated for vital signs (blood pressure, pulse rate, and respiratory 
rate) and PFTs (spirometry, l ung volumes, and DLco), and will be presented for each time point by 
study group (absolute values and change from baseline). Vital sign abnormalities and PFTs will be 
listed with a flag for clinical significance based on investigator judgment. Oral temperature data 
will be listed.
Chest CT scan results will be described narrati vely if abnormalities are reported during the study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Usewill ill 
odel. odel. 
ed effectd effec
he he 
rd error d erro
ersubjectsubje
SM will bM wil
rom tm the he
formulatrmu
d using ausing
, period,, period
fect. Eacct. Eac
E associE assoc
ance, alonce, a
will be cll be 
m ththe anae an
will be lwill be
ing descrg des
as one ps one 
to ident iden i
ercentagecentag
d PreferrPrefe
o studyo study y
r frequenfrequ
scriptscript iveiv
ateate) and) an
studystud
listCCI
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 64of 92
Protocol Incorporating Amendment 03 13 November 2018
ECG resul ts (abso lute values and change from baseline) will be summarized using descript ive 
statistics; frequencies (numbers and percentages) will be calculated for the overall evaluat ion by 
scheduled time and study  group.
Laboratory  data will be summarized by the ty pe of laboratory  test and chronol ogical time po int. 
Descript ive statistics and the n umber of subjects wit h laboratory  test resul ts bel ow, wi thin, and 
above normal ranges will be tabulated by  scheduled time. Abnormal findings in laboratory  data 
will be listed with a flag for clinical significance based on invest igator judgment.
Medical his tory abnormalit ies will be coded to MedDRA terms (version 20.0 or higher). Physical 
examinat ion abnormalit ies will also be listed.
The ori ginal  verbat im terms co llected in the eCRF for concomitant medicat ions will be coded 
using the WHO Drug Dict ionary into drug cl ass (Anatomical Therapeut ic Chemical classificat ion 
level 2) and preferred term. These data will be listed. 
Safety analyses will be conducted separately  for subjects who received TAK -788 and pl acebo. 
13.2 Determination of Sample Size
Part 1: The samp le size o f approximately  56 subjects i s determined on the basis of clinical rather 
than statist ical considerations. The number of subjects in this part of study is consistent with phase 
1 dose -finding studies.
Part 2 : Wit h a sample size of 14 healt hy subje cts, the 90% CI for the AUC rat io is expected to be in 
the range of 84% to 119%, using an intrasubject AUC variabilit y of 27% in pat ients with cancer 
and assuming a TAK -788 AUC ratio of 1 in the fed versus fasted comparison. After accounting for 
2 potentia l dropouts in Part 2, the final sample size is up to 16 healthy  subjects. Thi s sample size 
assumes no replacement of subjects who may drop out of the study  before the com pleting the PK 
sample collect ions in Part 2.
Part 3 With a sample size of 10 healt hy subjects, the 90% CI for the C maxratio is expected to be in 
the range of 87% to 115%, using an intrasubject C maxvariabilit y of 17% est imated in healt hy 
subjects. After accounting for 2 potential dropouts in Part 3, the final sample size allows for up to 
12 healthy subjects. This sample size assumes no replacement of subjects who may drop out of the 
study  before the com pleting the PK sample co llections in Part 3.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 65of 92
Protocol Incorporating Amendment 03 13 November 2018
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
Moni toring visit s to the stu dy site will be made periodically during the study to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and reco rds. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or i ts 
designee (eg, CRO) and by the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or designee 
(as long as blind ing is not jeopardized), including but not limited to the invest igator’s binder, study 
medicat ion, subject medical records, informed consent documentation, documentation of subject 
authori zation to use personal healt h informat ion (if separate from the ICFs ), and review of eCRFs 
and associated source documents. It is important that the invest igator and other study personnel are 
available during the monitoring visit s and that sufficient time is devoted to the process.
14.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with th e sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB or IEC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, inc rease the health risk to the subject, or confound interpretation of primary  study  
assessment. 
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the US Food and Drug Administration [FDA], the United 
Kingdo m [UK] Medicines and Healt hcare products Regulatory  Agency, the Pharmaceuticals and 
Medical Devices Agency of Japan). If the study  site is contacted for an inspection by  a regulatory 
body , the sponsor should be notified immediately . The investi gator and inst itution guarantee 
access for q uality assurance audi tors to all study  docum ents as described in Sect ion14.1.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 66of 92
Protocol Incorporating Amendment 03 13 November 2018
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the h ighest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” listed in Appendix B. The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal requirements of 
each parti cipat ing region. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has d irect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. US sites that are unwilling to provide names and tit les of all 
members due to privacy  and conflict of interest concerns should instea d provi de a Federal  Wide 
Assurance Number or comparable number assigned by the US Department of Healt h and Human 
Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and appr oval. This protocol , the investigator’s brochure, a copy  of 
the ICF, and, if applicable, subject recruitment materials and/or advertisements and other 
docum ents requi red by all applicable l aws and regul ations, m ust be submitted to a central or local 
IRB or IEC for approval. The IRB’s or IEC’s written approval o f the protocol  and subject 
inform ed consent m ust be obtained and submitted to the sponsor or designee before 
commencement of the study  (ie, before shipment of the sponsor -supplied drug or study specif ic 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; ident ify versio ns of other documents (eg, ICF) reviewed; and state the 
approval  date. The sponsor will notify  site once the sponsor h as confirmed the adequacy of site 
regul atory  docum entati on and, when applicable, the sponsor has received permissio n from 
competent authori ty to begin the tri al. Until  the si te receives notification, no protocol activit ies 
including screening may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruit ment 
materi als intended for viewing by  subjects, l ocal safety reporti ng requirements, reports and 
updates regarding the ongoing review of the study  at intervals specified by the respect ive IRB or 
IEC, and submissio n of the invest igator’s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati onfor these items must be provided to the sponsor or its 
designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 67of 92
Protocol Incorporating Amendment 03 13 November 2018
15.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, subject authorizat ion form (if applicable), and subject 
inform ation sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the subject’s personal and personal healt h informat ion for purposes of conducting 
the study . The ICF and the subj ect inform ation sheet (if applicable) further explain the nature of 
the study , its obj ectives, and potential risks and benefits, as well as the date informed consent is 
given. The ICF will detail the requirements of the participant and the fact that he or she is free to 
withdraw at any  time wi thout giving a reason and without prejudice to his or her further medical 
care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and if applicable, the subject authorizat ion form. The ICF, subject authorization form (if 
applicable), and subject informat ion sheet (if applicable) must be approved by both the IRB or IEC 
and the sponsor before use.
The ICF, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) 
must be written in a language that is fully co mprehensible to the prospective subject. It is the 
responsibilit y of the invest igator to explain the detailed elements of the ICF, subject authorizat ion 
form (if applicable), and subject inf ormation sheet (if applicable) to the subject. Informat ion 
shoul d be given in both oral  and wri tten form  whenever possible and in the manner deemed 
appropriate by the IRB or IEC. In the event the subject is not capable of rendering adequate written 
inform ed consent, then the subject’s legally  acceptable representative may  provide such consent 
for the subject in accordance with applicable laws and regulations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines that he or she will participate 
in the study , then the ICF and subject author ization form  (if applicable) must be signed and dated 
by the subject, or the subject’s legally acceptable representative, at the time of consent and before 
the subject enters into the study . The subject or the subject’s legally  acceptable representative 
should be instructed to si gn using thei r legal names, not ni cknames, using blue or black ballpo int 
ink pen. The invest igator must also sign and date the ICF and subject authorizat ion (if applicable) 
at the time o f consent and before subject entering into thestudy; however, the sponsor may allow a 
designee of the investigator to sign to the extent permitted by  applicable l aw.
Once signed, the original ICF, subject authorizat ion form (if applicable), and subject informat ion 
sheet (if applicable) will be stored in the investigator’s site file. The investigator must document 
the date the subject signs the ICF in the subject’s medical record. Copies of the signed ICF, the 
signed subject authori zation form (if applicable), and subject informat ion sheet (if applicab le) 
shall be given to the subject.
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 68of 92
Protocol Incorporating Amendment 03 13 November 2018
consent. The date the revised con sent was obtained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised ICF.
15.3 Subject Confidentiality
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against i nvasio n of privacy. Throughout this study , a subject’s source data will be linked to the 
sponsor’s clinical study  database or documentation only via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attrib utes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requires the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, US FDA, UK Medicines and Healt hcare products Regulatory  Agency, 
Japan Pharmaceut icals and Medical Devices Agency ), the sponsor’s designate d audi tors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents) including, but not limited to, laboratory test resul t reports, ECG reports, admissio n and 
discharge summaries for hospital admissio ns occurring during a subject’s study participation, and 
autopsy  reports. Access to a subject’s original medical records requires the specific authorizat ion 
by the subject as part of the informed consent process (see Sect ion15.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other iden tifier fields 
not collected on the subject’s eCRF).
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication 
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, a ny public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and advert isements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion from the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the docum ent. All publicat ions and presentations must be prepared in accordance with 
this secti on and the clinical study  site agreement. In the event of any discrepancy between the 
protocol  and the clinical study  site agreement, the clinical study  site agreement wi ll prevail. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 69of 92
Protocol Incorporating Amendment 03 13 November 2018
15.4.2 Clinical Trial Registration
To ensure that information on clinical trials reaches the public in a timely manner and to comply 
with applicable laws, regulat ions and guidance, Takeda will, at a minimum register intervent ional 
clinical trials it sponsors anywhere in the world on ClinicalTrials.gov or other publicly accessible 
websites on or before start of study , as defined in Takeda Policy/Standard . Takeda contact 
inform ation, along wi th invest igator’s cit y, state (for Americas investigators), co untry , and 
recrui ting status will be registered and available for public viewing. 
As needed Takeda and invest igator/site contact information may be made public to support 
participant access to trials via registries. In certain situations/registries, Taked a may assist 
participants or potential part icipants wi th finding a clinical trial by helping them locate trial sites 
closest to thei r homes by providing the investigator name, address, and phone number via 
email/phone or other methods to those requesting t rial information. Once subjects receive 
investigator contact information, they  may call  the si te to request enrollment into the trial. The 
investigat ive sites are encouraged to handle the trial inquiries according to their established subject 
screening pro cess. If the caller asks addit ional questions beyo nd the topic of trial enrollment, they 
shoul d be referred to the sponsor.
Any invest igator who objects to Takeda providing this informat ion to callers must provide Takeda 
with a wri tten noti ce request ing that their informat ion not be listed on the registry site. 
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov or other publicly  accessible 
websites (including the Takeda corporate site) and registries, a s requi red by Takeda Policy/
Standard, applicable laws and/or regulat ions. 
15.4.4 Data Sharing
The sponsor is committed to responsible sharing of clinical data with the goal of advancing 
medical science and improving subject care. Qualified independent researche rs will be permitted 
to use data collected fro m subjects during the study to conduct addit ional scient ific research, which 
may be unrelated to the study  drug or the subject’s disease. The data provided to external 
researchers will not include informat ion that identifies subjects personally. 
15.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the clinical study  site agreement for the sponsor’s policy  on subject com pensati on and 
treatm ent for injury. If the invest igator has questions regarding this policy, he or she should contact 
the sponsor or sponsor’s designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 70of 92
Protocol Incorporating Amendment 03 13 November 2018
16.0 REFERENCES
1. Kris M, Johnson B, Berry  L, Kwiatkowski D, Iafrate A, Wistuba I, et al. Using mult iplexed 
assays o f oncogenic drivers in lung cancers to select targeted drugs. JAMA 
2014;311(19):1998 -2006.
2. Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. E GFR mutation testing 
practi ces wi thin the Asia Pacific region: results of a mult icenter di agnosti c survey. J Thorac 
Onco l 2015;10(3):438 -45.
3. Murray  S, Dahabreh I, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P. Somatic 
mutati ons of the ty rosine kina se dom ain of epidermal growth factor receptor and ty rosine 
kinase inhibitor response to TKIs in non -small cell l ung cancer: an analy tical database. J 
Thorac Oncol 2008;3(8):832-9.
4. Hirsh V. Next- Generat ion Covalent Irreversible Kinase Inhibitors in NSCLC : Focus on 
Afatinib. BioDrugs 2015;29(3):167 -83.
5. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M 
mutati on in EGFR kinase causes drug resistance by  increasing the affinit y for ATP. Proc 
Natl Acad Sci  U S A 2008;105(6):2070 -5.
6. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and 
complementary  role of MET am plificati on and EGFR T790M mutation in acquired 
resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010;16(22):5489 -
98.
7. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, et al. Clinical act ivity of 
afatinib in pat ients with advanced non -small -cell lung cancer harbouring uncommo n EGFR 
mutati ons: a combined post -hoc analysis o f LUX -Lung 2, LUX -Lung 3, and LUX -Lung 6. 
Lancet Onco l 2015;16(7):830 -8.
8. Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney  M, et al . Natural  
history  and m olecular characterist ics of lung cancers harboring EGFR exon 20 insert ions. J 
Thorac Oncol 2013;8(2):179-84.
9. Wu JY, Wu SG, Ya ng CH, Gow CH, Chang YL, Yu CJ, et al. Lung cancer with epidermal 
growth factor receptor exon 20 mutations is associated with poor gefit inib treatment 
response. Clin Cancer Res 2008;14(15):4877 -82.
10. Naidoo J, Sima CS, Rodri guez K, Busby N, Nafa K, Ladan yi M, et al. Epidermal growth 
factor receptor exon 20 insert ions in advanced lung adenocarcino mas: Clinical outcomes and 
response to erlotinib. Cancer 2015;121(18):3212 -20.
11. Arcila ME, Nafa K, Chaft JE, Rekht man N, Lau C, Reva BA, et al. EGFR exon 20 in sertion 
mutati ons in lung adenocarcino mas: prevalence, molecular heterogeneit y, and 
clinicopathologic characterist ics. Mo l Cancer Ther 2013;12(2):220 -9.
12. Arcila ME, Chaft JE, Nafa K, Roy -Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, 
clinicopatholo gic associ ations, and mo lecular spectrum of ERBB2 (HER2) ty rosine kinase 
mutati ons in lung adenocarcino mas. Clin Cancer Res 2012;18(18):4910 -8.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 71of 92
Protocol Incorporating Amendment 03 13 November 2018
13. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, et al. Somat ic 
mutati ons of the HER2 kinas e dom ain in lung adenocarcinomas. Cancer Res 
2005;65(5):1642 -6.
14. Tomi zawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, et al. Prognostic and 
predi ctive implicat ions of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 
2011;74(1):139 -44.
15. ZYTIGA (abiraterone acetate) Tablets [package insert]. Horsham, PA: Janssen Biotech, Inc., 
2013.
16. Zykadia. Cerit inib EU Product Informat ion. Nuremberg, Germany: Novartis Pharma GmbH.
17. Commo n Termino logy Criteria for Adverse Events (CTCAE), Version 5.0. U.S. Department 
of Heal th and Human Services National Cancer Institute. 27 Nov 2017.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 72of 92
Protocol Incorporating Amendment 03 13 November 2018
Appendix ASchedule of Events
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 73of 92
Protocol Incorporating Amendment 03 13 November 2018
CONFIDENTIALTable 1 – Single Rising Dose Study (Part 1)
Screening aDay -1 Day 1 Day 2 Day 3 Day 8 Follow -up b
Informed consent X
Inclusion/exclusion criteria X X
Demographics X
Medical history X
Physical examination cX X X
Height X
Weight cX X
Vital signs dX X X X X
Chest CT scan eX (X)
Pulmonary function tests fX X
Concomitant medications and procedures gX
Adverse event reporting hX
Electrocardiogram iX X X X
Admission to clinical site jX
TAK -788 administration X
Pregnancy test kX X
Hematology/chemistry/coagulation lX X X X
Urinalysis lX X X X
Pharmacokinetic sampling mX X X X
Drug, alcohol, and tobacco testing nX X
Serology lX
Follow -up questionnaire X X
Footnotes are on last table page.continuous
continuous
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 74of 92
Protocol Incorporating Amendment 03 13 November 2018
CONFIDENTIALAbbreviations: CT, computed tomography; ICF, informed consent form.
An “X” in parentheses indicates that a procedure or test may be done under certain conditions. If extenuating circumstances p revent a subject from beginning treatment or completing 
a scheduled procedure or assessment within this time, the subject may conti nue the study only with the permission of the medical monitor. 
aUnless otherwise noted, the screening visit must occur within 21 days before the day of the first dose of study drug (Day 1). The ICF may be signed 2 -28 days before Day 1, and the 
chest CT s can may be within 28 days from Day 1 dosing.
bFollow- up phone call to query subject about possible adverse events. This contact should take place 30 days after the last dose (win dow of up to 2 days after Day 30). 
cThe Day -1 phy sical examination and wei ght assessment are not required if the screening physical examination and weight assessment were conducted within 4 -7 days before 
administration of the first dose of study drug (Day 1) and in the opinion of the investigator, there is no reason to believe t hey have substantially changed .
dPerform vital sign measurement before dosing. On Day 1 only, perform vital signs measurements between 4 and 6 hours postdose. Blood pressure should be determined with the 
subject in a seated position after sitting quietly for 5 minutes. See Section 9.4.6 for timing in relation to other tests and procedures. If vital sign measurement results are abnormal, a 
repeat measure may be taken within 30 minut es. 
eThe screening chest CT scan can be a low -dose CT scan within 28 days from Day 1 dosing. The follow- up chest scan, if needed based on symptoms, should be a high -resolution chest 
CT scan with the appropriate dose of radiation. No IV contrast agent sho uld be used. CT is to be performed on Day 3 if indicated based on pulmonary symptoms. 
fSee Section 9.4.7 . Part 1: Spirometry, lung volumes, and di ffusion capacity at screening but no more than 7 days before Day 1 and on Day 3.
gSee Section 9.4.10 . 
hSee Section 9.4.11 . 
iSee Section 9.4.13 . Triplicate 12 -lead ECG measurements must be taken at screening and on Day -1, Day 1, and Day 3. On Day 1 only, perform ECG measurements between 4 and 
6hours postdose. 
jSubjects should be admitted to the clinical site on the day before each dosing day. 
kA serum -human chorionic gonadotr opin pregnancy test will be performed only for subjects of childbearing potential during screening and again at Day -1 (baseline) if the 
screening test was performed more than 4 days before the first dose of any study drug. The results must be negative wit hin 4 days before the first dose of TAK- 788 is administered (ie, 
within the 4 days before Day 1), or as otherwise required by local regulations. Additional pregnancy testing may be performed during the s tudy at the discretion of the investigator, 
upon requ est from an independent ethics committee/institutional review board, or if required by local regulations. See Section 9.4.9 . 
lEvaluations to be p erformed are listed in Table 9.a. On Day 1 only, perform these laboratory tests between 4 and 6 hours postdose unless the timing of test is specified in 
Section 9.4.15 . 
mTime points for blood samples for PK analysis will be collected as specified in Appendix A, Tab le 3. 
nSee Sections 9.4.8 . 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 75of 92
Protocol Incorporating Amendment 03 13 November 2018
CONFIDENTIALTable 2 –Food Effect Study (Part 2) 
Screening aPeriod 1  Day -1 Day 1 Day 2 Day 3 Day 8
Follow -up bPeriod 2  Day 7 Day 8 Day 9 Day 10 Day 15
Informed consent X
Inclusion/exclusion criteria X X
Demographics X
Medical history X
Physical examination cX X X
Height X
Weight cX X
Vital signs dX X X X X
Chest CT scan eX (X)
Pulmonary function tests fX (X)
Concomitant medications and 
procedures g X
Adverse event reporting hX
Electrocardiogram iX X X X
Admission to clinical site jX
TAK -788 administration X
Pregnancy test kX X
Hematology/chemistry/coagulation lX X X X
Urinalysis lX X X X
Pharmacokinetic sampling mX X X X
Drug, alcohol, and tobacco testing nX X
Serology lX
Follow -up questionnaire X X
Footnotes are on last table page.continuous
continuous
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 76of 92
Protocol Incorporating Amendment 03 13 November 2018
CONFIDENTIALCT, computed tomography; ICF, informed consent form.
An “X” in parentheses indicates that a procedure or test may be done under certain conditions. Note: If extenuating circumstances prevent a subject from beginning treatment or 
completing a scheduled procedure or assessment within this time, the subject may continue the study only with the permission of the medical monitor.
aUnless otherwise noted, the s creening visit must occur within 21 days before the day of the first dose of study drug (Day 1). The ICF may be signed 2 -28 days before Day 1, and the 
chest CT scan may be within 28 days from Day 1 dosing.
bFollow- up phone call to query subject about poss ible adverse events. This contact should take place 30 days after the last dose (window of up to 2 days after Day 38). 
cThe Day -1 physical examination and weight are not required if the screening physical examination and weight were conducted within 4-7 days before administration of the first dose 
of study drug (Day 1) and in the opinion of the investigator, there is no reason to believe they have substantially changed. 
dPerform vital sign measurement before dosing. On Day 1 and Day 8, perform vital sig ns measurements between 4 and 6 hours postdose. Blood pressure should be determined with 
the subject in a seated position after sitting quietly for 5 minutes. See Section 9.4.6 for timing in relation to other tests and procedures. If vital sign measurement results are abnormal, 
a repeat measure may be taken within 30 minutes. 
eThe screening chest CT scan can be a low -dose CT scan within 28 days from Day 1 dosing. The follow -up chest scan, if needed based on symptoms, should be a high -resolution 
chest CT scan with the appropriate dose of radiation. No IV contrast agent should be used. CT is to be performed on Day 3 or Day 10 if indicated based on pulm onary symptoms. 
fSee Section 9.4.7 . Perform spirometry, lung volumes, and diffusion capacity at screening but no more than 7 days before Day 1. 
gSee Section 9.4.10 . 
hSee Section 9.4.11 . 
iSee Section 9.4.13 . Triplicate 12 -lead ECG measurements must be taken at screening and on Days -1, 1, 3, 7, 8, and 10. On Day 1 and Day 8, perform ECG measurements between 
4 and 6 postdose. 
jSubjects should be admitted to the clinical site on the day before each dosing day.
kA serum -human chorionic gonadotropin (-hCG) pregnancy test will be performed only for subjects of childbearing potential during screening and again at Day -1 (baseline) if the 
screening test was performed more than 4 days before the first dose of any study  drug. The results must be negative within 4 days before the first dose of TAK -788 is administered (ie, 
within the 4 days before Day 1), or as otherwise required by local regulations. In Period 2, the results must be negative on Day 7 before the seco nd single -dose of TAK -788 on Day 8 
is administered. Additional pregnancy testing may be performed during the study at the discretion of the investigator, upon r equest of an independent ethics committee 
(IEC)/institutional review board (IRB), or if required by local regulations. See Section 9.4.9 . 
lEvaluations to be performed are listed in Table 9.a. On Day 1 only, perform these laboratory tests between 4 and 6 hours postdose unless the timing of test is specified in 
Section 9.4.15 .
mTime points for blood samples for PK analysis will be collected as specified in Appendix A, Table 4. 
nSeeSections 9.4.8 . 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 77of 92
Protocol Incorporating Amendment 03 13 November 2018
CONFIDENTIALTable 3 Relative Bioavailability Study (Part 3)
Screening aPeriod 1  Day -1 Day 1 Day 2 Day 3 Day 8
Follow -up bPeriod 2  Day 7 Day 8 Day 9 Day 10 Day 15
Informed consent X
Inclusion/exclusion criteria X X
Demographics X
Medical history X
Physical examination cX X X
Height X
Weight cX X
Vital signs dX X X X X
Pulmonary function tests eX (X)
Concomitant medications and 
procedures f X
Adverse event reporting gX
ECG hX X X X
Admission to clinical site iX
TAK -788 administration X
Pregnancy test jX X
Hematology/chemistry/coagulation kX X X X
Urinalysis kX X X X
PK sampling lX X X
Drug, alcohol, and tobacco testing mX X
Serology kX
Follow -up questionnaire XnX
Footnotes are on last table page.continuous
continuous
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 78of 92
Protocol Incorporating Amendment 03 13 November 2018
CONFIDENTIALECG, electrocardiogram; ICF, informed consent form; PK, pharmacokinetic.
An “X” in parentheses indicates that a procedure or test may be done under certain conditions. Note: If extenuating circumstances prevent a subject from beginning tre atment or 
completing a scheduled procedure or assessment within this time, the subject may continue the study only with the permission of the medical monitor.
aUnless otherwise noted, the screening visit must occur within 21 days before the day of the fir st dose of study drug (Day 1). The ICF may be signed 2 -28 days before Day 1.
bFollow- up phone call to query subject about possible adverse events. This contact should take place 30 days after the last dose (win dow of up to 2 days after Day 38). 
cThe Day -1 physical examination and weight are not required if the screening physical examination and weight were conducted within 4-7 days before administration of the first dose 
of study drug (Day 1) and, in the opinion of the investigator, there is no reason t o believe they have substantially changed .
dPerform vital sign measurement before dosing. On Day 1 and Day 8, perform vital sign measurements between 4 and 6 hours postdose . Blood pressure should be determined with the 
subject in a seated position after sitting quietly for 5 minutes. See Section 9.4.6 for timing in relation to other tests and procedures. If vital sign measurement results are abnorma l, a 
repeat measure may be taken within 30 minutes. 
e See Section 9.4.7 . Perform spirometry, lung volumes, and diffusion capacity at screening but no more than 7 days before Day 1. 
fSee Section 9.4.10 . 
gSee Section 9.4.11 . 
hSee Section 9.4.13 . Tripli cate 12 -lead ECG measurements must be taken at screening and on Days -1, 1, 3, 7, 8, and 10. On Day 1 and Day 8, perform ECG measurements between 
4 and 6 postdose. 
iSubjects should be admitted to the clinical site on the day before each dosing day.
jA serum -human chorionic gonadotropin pregnancy test will be performed only for subjects of childbearing potential during screening and again at Day -1 (baseline) if the 
screening test was performed more than 4 days before the first dose of any study drug. T he results must be negative within 4 days before the first dose of TAK -788 is administered (ie, 
within the 4 days before Day 1), or as otherwise required by local regulations. In Period 2, the results must be negative on Day 7 before the second single -dose of TAK -788 on Day 8 
is administered. Additional pregnancy testing may be performed during the study at the discretion of the investigator, upon r equest of an independent ethics committee/institutional 
review board, or if required by local regulations. See Section 9.4.9 . 
kEvaluations to be performed are listed in Table 9.a. On Day 1 only, perform these laboratory tests between 4 and 6 hours postdose unless the timing of test is specified in 
Section 9.4.15 .
lTime points for blood samples for PK analysis will be collected as specified in Appendix A, Table 4. 
mSee Sections 9.4.8 .
n Day 15 safety conference call.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 79of 92
Protocol Incorporating Amendment 03 13 November 2018
Table 4 Pharmacokinetic Plasma and Urine Concentration Sampling Schedule for 
Part 1
Study DaySample 
Collection TimeTime 
(Relative to Dosing)
h:minPlasma Concentrations 
of TAK -788, AP32960, 
and AP32914Urine Concentrations 
of TAK -788, AP32960, 
and AP32914
1 0 h
(predose)00:00
(predose) (predose void)
0.5 h 00:30 (±5 min) 
1 h 01:00 (±10 min) 
2 h 02:00 (±10 min) 
4 h 04:00 (±10 min) 
6 h 06:00 (±20 min) 
8 h 08:00 (±20 min) 
12 h 12:00 (±20 min)  (0-12 h ±30 min )
2 0 h 24:00 (±30 min)  (12-24 h ±30 min )
12 h 36:00 (±30 min)  (24-36 h ±30 min )
3 0 h 48:00 (±30 min)  (36-48 h ±30 min )
4 0 h 72:00 (±60 min) 
5 0 h 96:00 (±60 min) 
8 0 h 168:00 (±60 min) 
Number of samples per profile: 14 4
When the timing of a PK or safety laboratory blood sample coincides with the timing of ECG measurements, the ECG 
will be completed before the collection of the blood sample. 
The timing of the morning visit on Days 4, 5, and 8 should occur at approximately the same time as the morning dosing 
time on Day 1. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 80of 92
Protocol Incorporating Amendment 03 13 November 2018
Table 5 Pharmacokinetic Plasma Concentration Sampling Schedule for Parts 2 and 3
Study Day Sample Collection TimeTime 
(Relative to Dosing)
h:minPlasma Concentrations of 
TAK -788, AP32960, and AP32914
1 0 h
(predose)00:00
(predose)
0.5 h 00:30 (±5 min) 
1 h 01:00 (±10 min) 
2 h 02:00 (±10 min) 
4 h 04:00 (±10 min) 
6 h 06:00 (±20 min) 
8 h 08:00 (±20 min) 
12 h 12:00 (±20 min) 
2 0 h 24:00 (±30 min) 
12 h 36:00 (±30 min) 
3 0 h 48:00 (±30 min) 
4 0 h 72:00 (±60 min) 
5 b0 h 96:00 (±60 min) 
8 c0 h 168:00 (±60 min) a
(predose)
0.5 h 00:30 (±5 min) 
1 h 01:00 (±10 min) 
2 h 02:00 (±10 min) 
4 h 04:00 (±10 min) 
6 h 06:00 (±20 min) 
8 h 08:00 (±20 min) 
12 h 12:00 (±20 min) 
9 0 h 24:00 (±30 min) 
12 h 36:00 (±30 min) 
10 0 h 48:00 (±30 min) 
11 0 h 72:00 (±60 min) 
12 b0 h 96:00 (±60 min) 
15 b0 h 168:00 (±60 min) 
Number of samples per profile: Part 2: 27
Part 3: 24
Note: The timing of the morning visit on Days 4, 5, and 8 should occur at approximately the same time as the morning dosing time 
on Day 1. Similarly, the timing of the morning visit on Days 11, 12, and 15 should occur at approximately the same time as th e 
morni ng dosing time on Day 8. When the timing of a PK or safety laboratory blood sample coincides with the timing of ECG 
measurements, the ECG will be completed before the collection of the blood sample. 
aThe predose PK sample must be collected before the nex t dose even though the collection window implies it can be taken after. 
The Day 8 dose must be administered shortly after the PK sample is taken.
b Part 3 removed PK sampling at 96 -hour and 168 -hour timepoints. Part 3 last PK sample is at the 72 -hour timep oint
cDay 8, Part 3 will have predose sample, not the 168 -hour sample.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 81of 92
Protocol Incorporating Amendment 03 13 November 2018
Appendix BResponsibilities of the Investigator
Clinical research studies sponsored by the sponsor are subject to ICH GCP and all applicable loca l 
laws and regulations. The responsibilit ies imposed on invest igators by the US FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agree s to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, before the receipt of written 
approval  from relevant governing bodies/authorit ies.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the st udy are informed of 
these obligat ions.
5.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56 ICH, and local regulatory  requi rements.
6.Ensure that the IRB/IEC will be responsible for init ial review, conti nuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 m onths of study  com pletion.
7.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50 ICH and local 
regul ations, are m et.
8.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in t he subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each ICF should contain a subject authorizat ion section that 
describes the uses and disclosures of a subject’s personal informat ion (including personal 
healt h informat ion) that will take place in connect ion with the study. If an ICF does not include 
such a subject authorizat ion, then the investigator must obtain a separate subject authorizatio n 
form from each subject or the subject’s legally acceptable re presentative.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all in vesti gations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
10.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 82of 92
Protocol Incorporating Amendment 03 13 November 2018
11.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor.
12.Report adverse reacti ons to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 83of 92
Protocol Incorporating Amendment 03 13 November 2018
Appendix CInvestigator Consent to Use of Personal Information
Takeda will co llect and retain personal information of invest igator , including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
UK, US, and Japan), including the f ollowing:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, proc essed, and transferred by Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Prepara tion and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and i nvest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and resul ts on publicly  accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level o f protection as data protection laws in the invest igator’s 
own country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 84of 92
Protocol Incorporating Amendment 03 13 November 2018
Appendix DList of Strong Inhibitors and Inducers of CYP3A
Strong Inhibitors aStrong Inducers b
Boceprevir Carbamazepine
Clarithromycin Enzalutamide
Cobi cistat Mitotane
Conivaptan Phenytoin
Danoprevir and ritonavir Rifampin
Diltiazem St. Jo hn’s wort
Elvitegravir and ritonavir
Grapefruit juice
Idelalisib
Indinavir and ritonavir
Itraconazole
Ketoconazole
Lopinavir and ritonavir
Nefazodone
Nelfinavir
Paritaprevir and ritonavir and (ombitasvir and/or 
dasabuvir)
Posaconazole
Ritonavir
Saquinavir and ritonavir
Telaprevir
Tipranavir and ritonavir
Troleandomycin
Voriconazole
Abbreviation: CYP, cytochrome P450. 
afda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ 
ucm093664.htm#table3-2 (accessed 18 January 2018).
bfda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ 
ucm093664.htm#table3-3 (accessed 18 January 2018). 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 85of 92
Protocol Incorporating Amendment 03 13 November 2018
Appendix EDetailed Description of Amendments to Text
The primary  secti on(s) of the protocol affected by the changes in Amendment 03 are indicated. 
The corresponding text has been revised throughout the protocol. 
Change 1: Addit ion of Part 3 to assess the relat ive bioavailabilit y of TAK -788 capsules in healt hy 
subjects.
The primary  change occurs in the following sections:
Secti on 4.4Rationale for the Proposed Study .
Secti on 4.4.4 Rationale for Relat ive Bioavailabilit y Assessment (Part 3) .
Secti on 5.0STUDY OBJECTIVES AND ENDPOINTS.
Secti on 6.0Study  Design .
Secti on 6.1Overview of Study  Design.
New Secti on 6.1.3 Part 3 –Relat ive Bioavailabilit y
.
Secti on 6.2Number of Subjects .
New Secti on 8.1.3 Relat ive Bioavailabilit y (Part 3) .
Secti on 8.10 Descript ion of Investigational Agents .
Secti on
 9.3Treatment Group Assignments .
Secti on 9.4.7 Pulmonary Funct ion Tes ts
Secti on 13.1.3 PK Analysis .
Secti on 13.2 Determinat ion of Sample Size .
Appendix A Schedule o f Events .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 86of 92
Protocol Incorporating Amendment 03 13 November 2018
Added text: Section 4.4 Rationale for the Proposed St udy:
This study  is,proposed to ident ify characterize safet y and tolerabilit y of a single oral 
dose of TAK -788, to identify a safe and tolerable dose of TAK -788 administered as 
a drug -in-capsule (Di C) form ulation in healt hy subjects and,to evaluate the ef fects o f 
a low-fat meal on the PK of TAK -788 and i ts active m etabo lites,AP32960 and 
AP32916 , and to assess the relative bioavailability of 2 DiCs of TAK -788. Part 1 o f 
the study  will use a rando mized, double -blind, pl acebo -controlled, single rising dose 
escalat ion design to determine the safet y and tolerabilit y of TAK-788 and characterize 
the PK of TAK -788 and its act ive metabolites, and t o identify a tolerable single dose 
in healthy subjects. Part 2 of the study  will assess the effects of a low -fat meal on the 
PK of TAK -788 administered as a DiC formulat ion. Part 3 of the study will evaluate 
the relative bioavailability of a single dose of TAK -788 160 mg Process B DiC 
(test) versus a single dose of TAK -788 160 mg Process A DiC (reference).
Section 4.4.4 Rationale for Relative Bioavailability Assessment (Part 3)
Process A and Process B TAK -788 drug substance (succinate salt) are chemically 
identical but are synthesized by different synthetic routes. The physiochemical 
properties of Process A and Process B TAK- 788 drug substance are, however, 
different. The API powder prepared via Process B has larger primary particles, 
lower specific surface area, and a higher bulk density than the API powder 
prepared via Process A. The rationale for Part 3 of the study is to perform 
relative bioavailability assessment of Process B versus Process A DiC to enable 
PK bridging across the patients who are using o r will be using these 2 DiCs in the 
TAK -788 clinical development program. Part 3 of this study was added in 
Amendment 2 to assess the relative bioavailability of TAK- 788 encapsulated in 
Process B DiC (test) and Process A DiC (reference) in healthy subjects .
Section 5.0 STUDY OBJECTIVES AND ENDPOINTS
Section 5.1.1 Primary Objectives
The primary objectives are : 
Part 1: to To assess safet y and tol erabili ty of TAK -788 and to i dentify a tolerable 
single oral  dose of TAK -788 administered as a drug -in-capsule ( DiC)
formulation in healt hy subjects. 
Part 2 :toTocharacterize the effect sof a low-fat m eal on the PK of TAK -788 and its 
active metabo lites, AP32960 and AP32914, administered as a DiC 
formulation in healt hy subjects.
Part 3 :To evaluate the bioavailabilit y of a test (Process B) DiC of TAK -788 
relative to a reference (Process A) DiC of TAK- 788 in healthy subjects .
Section 5.1.2 Secondary Objectives
The secondary  objectives are: 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 87 of 92
Protocol Incorporating Amendment 03 13 November 2018
Part 1: to Tocharacterize the PK of TAK-788 and its active metabolites, AP32960 
and AP32914, administered as a DiC formulation in healthy subjects.
Part 2: to / Part 3 : To assess the safety of TAK-788 following a single dose of 
TAK-788 with or without a low-fat meal,  administered as a DiC formulation
in healthy subjects.
Section 5.1.3 Exploratory Objectives
The exploratory objective is: 
Section 5.2 Endpoints
Section 5.2.1 Primary Endpoints
The primary endpoints are: 
Part 1: safety profile of orally administered TAK-788. 
• number and percentage of subjects with 1 or more AEs.
• number and percentage of subjects with 1 or more SAEs.
• number and percentage of subjects with clinically defined abnormal laboratory 
values.
• number and percentage of subjects with clinically defined abnormal vital signs.
Part 2: summary statistics of the PK parameters for TAK-788 and its 2 active 
metabolites, AP32960 and AP32914 under fasted conditions or following a low-fat 
meal. 
•C max.
•t max.
• AUC t (area under the concentration-time curve from time 0 to time t).
• AUC ∞ (area under the first moment concentration-time curve from time 0 to 
infinity calculated using the last quantifiable concentration.
•t 1/2z(terminal disposition phase half-life).
Part 3:summary statistics of the PK parameters for TAK-788 with different DiC 
under fasted conditions. 
•C max.CCI
Property of Takeda: For non-commercial use only and subjministeriniste
f subjectssubjec
ge of subge of su
entage ofntage o
d percenperce
ummary mmary
litites,es,Aol. 
•CCma
•t•plicable Terms of UseulatlatioionnTer
bject to the appl
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 88 of 92
Protocol Incorporating Amendment 03 13 November 2018
•t max.
• AUC t.
• AUC ∞ (if data permitted).
•t 1/2z.
Section 5.2.2 Secondary Endpoints
The secondary endpoints are: Part 1: summary statistics of the PK parameters for TAK-788 and its 2 active 
metabolites, AP32960 and AP32914 under fasted conditions. 
•C
max.
•t max.
• AUC t.
• AUC ∞.
•t 1/2z.
Part 2: safety profile of TAK-788 under fas ted conditions or fo llowing a low-fat meal.
Part 3: safety profile of TAK-788 under fasted conditions.
Section 5.2.3 Exploratory EndpointsThe exploratory endpoint is: 
CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Usend its 2 ad its 2 
der fasteder fas
788 und8 un
Endpoinndpo
ntt is:  is: 
keda: For non-commercia
TAK-788 (formerly AP32788)
Study No. TAK-788- 1001 Page 89 of 92
Protocol Incorporating Amendment 03 13 November 2018
Section 6.1 Overview of Study Design
This is a randomized, double-blind, randomized, placebo- controlled, single rising 
dose study ,followed by a an open-label, crossover evaluation of the effects of a 
low-fat meal on the PK of TAK-788 PK and its 2 active metabolites in healthy 
subjects. , and a crossover evaluation of the relative bioavailability of TAK-788 
Process B DiC (test) versus Process A DiC (reference) in healthy subjects under 
fasting conditions. Following the completion of Part 1 (dose escalation phase) 
where a safe and tolerable dose in healthy subjects will be identified, Part 2 (food 
effect phase) and Part 3 (relative bioavailability of TAK-788 capsules) will be 
initiated where the effects of a low-fat meal on TAK-788 and the relative 
bioavailability of TAK-788 in test versus reference will be studied .
Section 6.1 Overview of the Design…
Section 6.1.3 Part 3 – Relative Bioavailability
The purpose of Part 3 is to evaluate the bioavailability of a test DiC of TAK-788 
relative to a reference DiC of TAK-788. Part 3 of the study will be open-label. 
Subjects will be randomly assigned to a crossover sequence at a 1:1 ratio and 
administered a single dose of 160 mg TAK-788 capsule A DiC (reference) or 
160 mg TAK-788 capsule B DiC (test) on Day 1 in Period 1 and on Day 8 in 
Period 2 under fasting conditions, with a planned washout period of 7 days. 
PFTs (spirometry, lung volumes, and DLco) are required to be performed and 
assessed as normal at screening. PFTs will be performed on Day 3, Day 10, 
and/or Early Termination visit in Part 3 only if indicated on the basis of 
pulmonary symptoms; no chest CT scans will be done. Other clinical study 
procedures are the same as those in the dose escalation phase. Subjects will have 
PK collection samples collected during confinement, and the last PK sample will 
be collected at 72 hours postdose in each period. Subjects will be furloughed 
after the last PK sample collection in Period 1. Subjects will return to the clinical 
study site on Day 7 for Period 2 study. Subjects will be released from the clinical 
study site after the last PK sample collection in Period 2. Safety phone 
conferences will occur on Day 15 and 30 days after the last dose (window of up to 
2 days after Day 38).
Figure 6.c Relative Bioavailability Schema (Part 3)CCI
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Used,singlesingllthe effeche effe
olittes ines i
availabilvailab
) i) in healn he
rt 1 (dos 1 (do
cts will bcts will
ity of Tty of T
l on TAon TA
s refererefer
ve Bioave Bio
to evaluto eva
DiC ofDiC o
andomlndom
a single dsingle
K-788 ca788 c
under fander
spiromepirom
ssed as sed a
nd/or End/or 
pulmopulm
propr
PT
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 90of 92
Protocol Incorporating Amendment 03 13 November 2018
[New figure depicting Part 3 schema]
Section 6.2 Number of Subjects
...
Part 3: With a sample size of 10 healthy subjects, the 90% CI for the C maxratio is 
expected to be in the range of 87% to 115%, using an intrasubject C max
variability of 17% estimated in healthy subjects. After accounting for 2 potential 
dropouts in Part 3, the final sample size is up to 12 healthy subjects. This sample 
size ass umes no replacement of subjects who may drop out of the study before 
the completing the PK sample collections in Part 3.
Section 8.1.3 Relative Bioavailability (Part 3)
Subjects in Part 3 will receive a single dose of TAK- 788 160 mg test DiC 
(Process B) or a single dose of TAK -788 160 mg reference DiC (Process A) under 
fasted conditions on Day 1 or Day 8 following an overnight fast of at least 
10hours. The drug product should be administered with 240 mL (8 fluid ounces) 
of water. No food should be allowed for at least 4 hours postdose.
Water can be allowed as desired except for 1 hour before and after drug 
administration. Subjects should receive standardized meals scheduled at the 
same time in each period of the study.
Section 8.10 Description of Investigat ional Agents
TAK -788 drug product is a nonsterile oral DiC formulat ion. The active study  drug i s 
available as 20 or 40 mg dosage strength capsules. The API has been synt hesized 
using 2 different processes (Process A and Process B). Before Amendment 1, all 
subjects in Part 1 of this study received TAK -788 from  Process B unmilled only with 
the capsule strength of 20 mg , and subjects in Part 2 received TAK -788 f rom 
Process A with capsule strength of 20 mg. After Amendment 1, some addit ional 
cohorts in Part 1 m ay receive TAK -788 fro m Process A.
Process A and Process B are the same succinate salt in chemical structure but 
synthesized with different physical properties. Process B incorporates optimizat ions 
in scale up, solvents, and reagents and implements a new s tep.processes . The API 
from Process B has larger particle size and higher bulk densit y than that from  
Process A. At the time of Amendment 1, preliminary  PK data from this study  and a 
phase 1/2 study  in pat ients with NSCLC (Study  AP32788 -15-101) indicate 
approximately  30% to 60% l ower exposures (TAK -788 AUC 24) in healt hy subjects 
receiving Process B unmilled TAK -788 DiC com pared wi th patients wi th NSCLC 
receiving Process A TAK- 788 DiC.
Section 9.3 Treatment Group Assignments
...
In Part 3, subjects will receive TAK -788 Process B DiC (test) or Process A DiC 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 91of 92
Protocol Incorporating Amendment 03 13 November 2018
(reference), then crossover to receive the alternate TAK -788 (test or reference) 
formulation after a washout of at least 7 days between doses of TAK -788.
Section 9.4.7 Pulmonary Function Tests
PFTs include spirometry, lung vo lumes, and DLco. In Part 1, PFTs will be performed 
at screening but no more than 7 days before Day 1, and at Day 3 before furlough. In 
Parts 2and 3 , PFTs will be performed at screening and at Day  3, Day 10, and/or 
Early Termination visit if indicated on the basis of pulmo nary symptoms. 
Section 13.1.3 PK Analysis
Descript ive statistics, including arithmet ic mean, geometric mean, SD, coefficient of 
variat ion (%CV), minimum, median, and maximum, will be calcula ted and presented 
by dose level in Part 1 and,for each treatment under fasted versus fed condit ions in 
Part 2 , and for each treatment (test vs reference drug formulation) under fasted 
conditions in Part 3 for plasma concentrati ons of TAK -788 and its 2 act ive 
metabo lites, AP32960 and AP32914.
...
In Part 3, PK parameters (ln -transformed) of TAK -788 for the test formulation 
(Process B DiC) and the reference formulation (Process A DiC) will be compared 
using an ANOVA model. The ANOVA model will include treatm ent (test versus 
reference), period, and sequence as fixed effects and subject nested within 
sequence as a random effect. Each ANOVA will calculate the LSM, the 
difference between treatment LSMs, and the SE associated with the difference. 
Residual, subject nested within sequence, and intersubject variance, along with 
the intrasubject and intersubject CV, will be reported. Ratios of LSM will be 
calculated using the exponential function of the difference between treatment 
LSMs from the analyses on the ln- transformed C max, AUC t, and AUC∞(if data 
permitted).
Section 13.2 Determination of Sample Size
...
Part 3 With a sample size of 10 healthy subjects, the 90% CI for the C maxratio is 
expected to be in the range of 87% to 115%, using an intrasubject C max
variabi lity of 17% estimated in healthy subjects. After accounting for 2 potential 
dropouts in Part 3, the final sample size allows for up to 12 healthy subjects. This 
sample size assumes no replacement of subjects who may drop out of the study 
before the complet ing the PK sample collections in Part 3.
Appendix A Schedule of Events
[Addit ion of Table 3 Relat ive Bioavailabilit y Study (Part 3)]
[Revised Table 5 Pharmacokinetic Plasma Concentration Sampling Schedule for 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -788 (formerly AP32788)
Study No. TAK -788-1001 Page 92of 92
Protocol Incorporating Amendment 03 13 November 2018
Parts 2 and 3 to i nclude PK sampling for Part 3] 
Rationale for Change: The rationale for Part 3 of the study is to perform relat ive bioavailabilit y 
assessment of Process B versus process A DiC to enable PK bridging across the patients who are 
using or wi ll be using these 2 DiCs in the TAK 788 clinical development program.
The fo llowing sect ions also contain this change:
Study  title.
Secti on 2.0STUDY SUMMARY .
Secti on 6.3.1 Duration of an Individual Subject’s Study  Parti cipat ion.
Table 6.a Primary and Secondary  Endpo ints for Di sclosures.
Secti on
 7.1Inclusion Criteria .
Secti on9.4.7 Pulmonary Funct ion Tes ts.
Secti on 9.4.8 Drug, Alcoho l, and Tobacco Testing .
Secti on 9.4.9 Pregnancy Test .
Secti on 9.4.11 AEs.
Secti on 9.4.12 Enrollment .
Secti on 9.4.13 ECG .
Secti on 9.4.14 Chest CT Scan .
Secti on 9.4.16 PK Measurements .
Secti on 9.5Com pletion of Study  Treatm ent for Individual Subjects .
Secti on 9.6Discont inuat ion of Treatment With Study  Drug and Subject Replacement.
Secti on 13.1.1 Analysis Sets . 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GE䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢵䢢䣶䣱䢢䢢䣒䣪䣣䣵䣧䢢䢳䢮䢢䣑䣲䣧䣰䢯䣎䣣䣤䣧䣮䢮䢢䣕䣫䣰䣩䣮䣧䢢䣔䣫䣵䣫䣰䣩䢢䣆䣱䣵䣧䢢䣕䣶䣷䣦䣻䢢䣶 䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢮䢢䣕䣣䣨䣧䣶䣻䢮䢢䣣䣰䣦
䣖䣱䣮䣧䣴䣣䣤䣫䣮䣫䣶䣻䢢䣱䣨䢢䣖䣃䣍䢯䢹䢺䢺䢢䣈䣱䣮䣮䣱䣹䣧䣦䢢䣤䣻䢢䣣䣅䣴䣱䣵䣵䣱䣸䣧䣴䢢䣇䣸䣣䣮䣷䣣䣶䣫䣱䣰䢢䣱䣨䢢䣶䣪 䣧䢢䣇䣨䣨䣧䣥䣶䣵䢢䣱䣨䢢䣣䢢䣎䣱䣹䢯䣈䣣䣶䢢䣏䣧䣣䣮䢢䣱䣰䢢䣶䣪䣧
䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢢䣱䣨䢢䣖䣃䣍䢯䢹䢺䢺䢢䣫䣰䢢䣊䣧䣣䣮䣶䣪䣻䢢䣕䣷䣤䣬䣧䣥䣶䣵
%LRVWDWLVWLFV$SSURYDO 1RY87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO 1RY87&
&OLQLFDO$SSURYDO 1RY87&PPD
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Useble Tate ate 
ablHH:mm ‘UH:mm eT
ab87&87&

1RY1RY